ketamine has been researched along with Affective Psychosis, Bipolar in 180 studies
Ketamine: A cyclohexanone derivative used for induction of anesthesia. Its mechanism of action is not well understood, but ketamine can block NMDA receptors (RECEPTORS, N-METHYL-D-ASPARTATE) and may interact with sigma receptors.
ketamine : A member of the class of cyclohexanones in which one of the hydrogens at position 2 is substituted by a 2-chlorophenyl group, while the other is substituted by a methylamino group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "While the psychiatric benefits of ketamine have been verified through clinical trials, there is limited information about ketamine augmentation in patients with treatment-resistant bipolar depression (TRBPD)." | 9.34 | Transient effects of multi-infusion ketamine augmentation on treatment-resistant depressive symptoms in patients with treatment-resistant bipolar depression - An open-label three-week pilot study. ( Chen, C; Ji, F; Jia, F; Jiang, D; Lin, X; Tian, H; Wang, L; Zhou, C; Zhu, J; Zhuo, C, 2020) |
| "Ketamine induces rapid and robust antidepressant effects, and many patients also describe dissociation, which is associated with antidepressant response." | 9.27 | Features of dissociation differentially predict antidepressant response to ketamine in treatment-resistant depression. ( Ballard, ED; Brutsche, NE; Farmer, C; Jaso, BA; Luckenbaugh, DA; Niciu, MJ; Park, LT; Shovestul, BJ; Zarate, CA, 2018) |
| "The results of this pilot study are inconclusive because they lack power to support an advantage of ketamine anesthesia compared with methohexital in ameliorating depressive symptoms for electroconvulsive therapy." | 9.24 | A Randomized Pilot Study Comparing Ketamine and Methohexital Anesthesia for Electroconvulsive Therapy in Patients With Depression. ( Eads, LA; Golden, K; Han, X; Ray-Griffith, SL; Stowe, ZN, 2017) |
| " Anhedonia occurs across psychiatric diagnoses and has been associated with specific neural circuits in response to rapid-acting treatments, such as ketamine." | 9.24 | Anhedonia as a clinical correlate of suicidal thoughts in clinical ketamine trials. ( Ameli, R; Ballard, ED; Brutsche, NE; Lally, N; Luckenbaugh, DA; Niciu, MJ; Park, L; Richards, EM; Walls, T; Wills, K; Zarate, CA, 2017) |
| "A linear mixed model showed that ketamine significantly lowered fatigue scores compared to placebo from 40 min post-treatment to Day 14 with the exception of Day 7." | 9.22 | An assessment of the anti-fatigue effects of ketamine from a double-blind, placebo-controlled, crossover study in bipolar disorder. ( Luckenbaugh, DA; Machado-Vieira, R; Saligan, LN; Slonena, EE; Zarate, CA, 2016) |
| " Ketamine has been shown to rapidly and robustly decrease symptoms of depression in depressed patients with bipolar disorder." | 9.20 | A single infusion of ketamine improves depression scores in patients with anxious bipolar depression. ( Ionescu, DF; Luckenbaugh, DA; Niciu, MJ; Richards, EM; Zarate, CA, 2015) |
| " We have previously shown that a single dose of ketamine, a glutamate N-methyl-d-aspartate (NMDA) receptor antagonist, is associated with a rapid reduction in depressive symptom severity and SI in patients with treatment-resistant depression." | 9.20 | Ketamine for rapid reduction of suicidal ideation: a randomized controlled trial. ( Brallier, JW; Charney, DS; Collins, KA; DeWilde, KE; Goodman, WK; Iacoviello, BM; Iosifescu, DV; Kautz, M; Kim, J; Lapidus, KA; Lener, M; Murrough, JW; Perez, AM; Price, RB; Rodriguez, GJ; Soleimani, L; Stern, JB, 2015) |
| "Ketamine, an N-methyl d-aspartate (NMDA) antagonist, has rapid antidepressant effects in depressed subjects with bipolar disorder (BD)." | 9.19 | Neural correlates of rapid antidepressant response to ketamine in bipolar disorder. ( Brutsche, N; Carlson, PJ; Diazgranados, N; Drevets, WC; Herscovitch, P; Ibrahim, L; Luckenbaugh, DA; Nugent, AC; Zarate, CA, 2014) |
| "In this double-blind, randomized, crossover, placebo-controlled study, 15 subjects with DSM-IV bipolar I or II depression maintained on therapeutic levels of lithium or valproate received a single intravenous infusion of either ketamine hydrochloride (." | 9.16 | Replication of ketamine's antidepressant efficacy in bipolar depression: a randomized controlled add-on trial. ( Brutsche, NE; Cravchik, A; Diazgranados, N; Franco-Chaves, J; Ibrahim, L; Liberty, V; Luckenbaugh, DA; Marquardt, CA; Selter, J; Zarate, CA, 2012) |
| " To assess the effects of ketamine and other glutamate receptor modulators in alleviating the acute symptoms of depression in people with bipolar disorder." | 9.12 | Ketamine and other glutamate receptor modulators for depression in adults with bipolar disorder. ( Barnes, A; Cipriani, A; Cowen, PJ; Dean, RL; Geddes, J; Hawton, K; Hurducas, C; Malhi, GS; Marquardt, T; McShane, R; Smith, R; Spyridi, S, 2021) |
| " Many studies have demonstrated the efficacy of ketamine in reducing depressive symptoms in adults with treatment-resistant mood disorders, though few studies utilizing ketamine in youth populations exist." | 9.12 | A systematic review of therapeutic ketamine use in children and adolescents with treatment-resistant mood disorders. ( Kim, S; Rice, TR; Rush, BS, 2021) |
| "The efficacy of ketamine in reducing suicidal ideation (SI) has been previously reported." | 9.12 | The acute antisuicidal effects of single-dose intravenous ketamine and intranasal esketamine in individuals with major depression and bipolar disorders: A systematic review and meta-analysis. ( Carvalho, I; Chen-Li, D; Gill, H; Lee, Y; Lipsitz, O; Lui, LMW; Mansur, RB; McIntyre, RS; Narsi, F; Rodrigues, NB; Rosenblat, JD; Xiong, J, 2021) |
| "The use of ketamine for depression has increased rapidly in the past decades." | 9.12 | Pharmacodynamic Interactions Between Ketamine and Psychiatric Medications Used in the Treatment of Depression: A Systematic Review. ( Bakker, IM; Kamphuis, J; Schoevers, RA; Smith-Apeldoorn, SY; Touw, DJ; Veraart, JKE; Visser, BAE, 2021) |
| " To assess the effects of ketamine and other glutamate receptor modulators in alleviating the acute symptoms of depression in people with bipolar disorder." | 8.91 | Ketamine and other glutamate receptor modulators for depression in bipolar disorder in adults. ( Amit, BH; Brett, D; Caddy, C; Cipriani, A; Diamond, PR; Hamadi, L; Hawton, K; Jochim, J; McCloud, TL; McShane, R; Rendell, JM; Shuttleworth, C, 2015) |
| "Depressive symptom severity and the affective index of pain partially mediated improvements in social function after six repeated ketamine treatments among patients with bipolar or unipolar depressive disorder." | 8.31 | Pain mediates the improvement of social functions of repeated intravenous ketamine in patients with unipolar and bipolar depression. ( Gan, Y; Hu, Z; Lan, X; Li, N; Li, W; Liu, H; Ning, Y; Wang, C; Wu, Z; Ye, Y; Zhang, F; Zhou, Y, 2023) |
| "This case presents a female patient diagnosed with both Bipolar Disorder (BD) and Borderline Personality Disorder (BPD) who received intravenous ketamine treatment to alleviate acute depressive symptoms." | 8.31 | Short term ketamine treatment in patient with bipolar disorder with comorbidity with borderline personality disorder: Focus on impulsivity. ( Cubała, WJ; Gałuszko-Węgielnik, M; Jakuszkowiak-Wojten, K; Wilkowska, A, 2023) |
| "This preliminary study found that repeated ketamine infusions appeared to be effective at rapidly ameliorating anhedonia, with similar efficacy in MDD and BD." | 8.12 | Comparative effectiveness of repeated ketamine infusions in treating anhedonia in bipolar and unipolar depression. ( Gu, LM; Lan, XF; Ning, YP; Sun, CH; Wang, CY; Zhang, B; Zheng, W; Zhou, YL, 2022) |
| "Although preliminary, present findings suggest that repeated subcutaneous esketamine infusions are effective for the treatment of anhedonia in both unipolar and bipolar depressed patients." | 8.02 | Comparative effectiveness of esketamine in the treatment of anhedonia in bipolar and unipolar depression. ( Barbosa, MG; Del-Porto, JA; Delfino, RS; Fava, VAR; Lacerda, ALT; Lucchese, AC; Magalhães, E; Nakahira, C; Sant, LCD; Sarin, LM; Steglich, MS; Surjan, J; Tuena, MA, 2021) |
| "Patients with TRD and prominent anxiety receiving IV ketamine exhibited a significant reduction in depressive, SI and anxiety symptoms." | 8.02 | The effectiveness of intravenous ketamine in adults with treatment-resistant major depressive disorder and bipolar disorder presenting with prominent anxiety: Results from the Canadian Rapid Treatment Center of Excellence. ( Gill, H; Ho, R; Kratiuk, K; Lee, Y; Lipsitz, O; Lui, LM; Mansur, RB; McIntyre, RS; Nasri, F; Rodrigues, NB; Rosenblat, JD; Subramaniapillai, M; Teopiz, K, 2021) |
| "We evaluated the effects of repeated subanesthetic ketamine infusions on suicidal ideation (SI) in patients with major depression." | 8.02 | Subanesthetic ketamine infusions for suicide ideation in patients with bipolar and unipolar treatment refractory depression. ( Anjum, MR; Chandrasena, R; Fairbairn, J; Hawken, ER; Kang, MJY; Kulcar, E; Vazquez, GH, 2021) |
| " Herein, we investigated whether pre-treatment functioning in outpatients with treatment-resistant depression (TRD) moderates response to intravenous (IV) ketamine." | 8.02 | Does pre-treatment functioning influence response to intravenous ketamine in adults with treatment-resistant depression? ( Cha, DS; Gill, H; Ho, RC; Kratiuk, K; Lee, Y; Lin, K; Lipsitz, O; Lui, LMW; Mansur, RB; McIntyre, RS; Nasri, F; Rodrigues, NB; Rosenblat, JD; Subramaniapillai, M; Teopiz, KM, 2021) |
| "To identify a meaningful change threshold (MCT) in depression outcomes in adults with treatment-resistant major depressive disorder (MDD) or bipolar disorder (BD) receiving intravenous ketamine treatment at a community-based mood disorders center." | 8.02 | The meaningful change threshold as measured by the 16-item quick inventory of depressive symptomatology in adults with treatment-resistant major depressive and bipolar disorder receiving intravenous ketamine. ( Gill, H; Ho, RC; Jones, BDM; Kratiuk, K; Lee, Y; Ling, R; Lipsitz, O; Lui, LMW; Mansur, RB; McIntyre, RS; Nasri, F; Rodrigues, NB; Rosenblat, JD; Subramaniapillai, M; Teopiz, KM, 2021) |
| "To determine the effectiveness of intravenous (IV) ketamine on anxiety, irritability, agitation, and suicidality, in adults with treatment-resistant major depressive disorder (MDD) or bipolar disorder (BD)." | 7.96 | The effectiveness of ketamine on anxiety, irritability, and agitation: Implications for treating mixed features in adults with major depressive or bipolar disorder. ( Cha, DS; Fagiolini, A; Gill, H; Ho, R; Kratiuk, K; Lee, Y; Lin, K; Lipsitz, O; Malhi, GS; Mansur, RB; McIntyre, RS; Nasri, F; Rodrigues, NB; Rosenblat, JD; Subramaniapillai, M; Suppes, T; Vinberg, M, 2020) |
| "The effectiveness, tolerability, and safety of intravenous (IV) ketamine in adults with treatment resistant depression (TRD) receiving care in real-word settings is insufficiently characterized." | 7.96 | The effectiveness of repeated intravenous ketamine on depressive symptoms, suicidal ideation and functional disability in adults with major depressive disorder and bipolar disorder: Results from the Canadian Rapid Treatment Center of Excellence. ( Abrishami, A; Arekapudi, AK; Brietzke, E; Carvalho, IP; Chau, EH; Gill, H; Kratiuk, K; Lee, Y; Lipsitz, O; Lui, LMW; Majeed, A; Mansur, RB; McIntyre, RS; Nasri, F; Phan, L; Rodrigues, NB; Rosenblat, JD; Senyk, O; Siegel, A; Subramaniapillai, M; Szpejda, W, 2020) |
| "After adjusting for age, sex, primary diagnosis, concomitant medication, body mass index, and baseline depression severity, there was a statistically significant reduction in symptoms of anhedonia with IV ketamine treatment (F (2, 235." | 7.96 | Changes in symptoms of anhedonia in adults with major depressive or bipolar disorder receiving IV ketamine: Results from the Canadian Rapid Treatment Center of Excellence. ( Cha, DS; Gill, H; Ho, R; Kratiuk, K; Lee, Y; Lin, K; Lipsitz, O; Majeed, A; Mansur, RB; McIntyre, RS; Nasri, F; Phan, L; Rodrigues, NB; Rosenblat, JD; Subramaniapillai, M, 2020) |
| " Previous studies found that ketamine intervention could rapidly reduce suicidal ideation in depression." | 7.91 | A preliminary study of anti-suicidal efficacy of repeated ketamine infusions in depression with suicidal ideation. ( Chen, L; Li, H; Li, M; Li, MD; Liu, W; Ning, Y; Walter, M; Wang, C; Yu, L; Zhan, Y; Zhang, B; Zheng, W; Zhou, Y, 2019) |
| "No pharmacological treatments exist for active suicidal ideation (SI), but the glutamatergic modulator ketamine elicits rapid changes in SI." | 7.88 | Characterizing the course of suicidal ideation response to ketamine. ( Ballard, ED; Farmer, CA; Kadriu, B; Machado-Vieira, R; Niciu, MJ; Park, L; Richards, E; Yarrington, JS; Yuan, P; Zarate, CA, 2018) |
| "Ketamine has rapid antidepressant effects on treatment-resistant depression, but the biological mechanism underpinning this effect is less clear." | 7.88 | Antidepressant effect of repeated ketamine administration on kynurenine pathway metabolites in patients with unipolar and bipolar depression. ( Chen, L; Li, H; Li, M; Liu, W; Ning, Y; Wang, C; Zhan, Y; Zheng, W; Zhou, Y, 2018) |
| "Ketamine is a standard anaesthetic drug that has been studied as a possible treatment for acute suicidal ideation." | 7.85 | Use of ketamine for acute suicidal ideation in a patient with chronic pain on prescribed cannabinoids. ( Bigman, D; Bobrin, B; Kunaparaju, S, 2017) |
| "Depression is disabling and highly prevalent." | 6.82 | International pooled patient-level meta-analysis of ketamine infusion for depression: In search of clinical moderators. ( Abdallah, CG; Ballard, ED; Baumeister, A; Blier, P; Charney, DS; Chen, MH; Deakin, W; Fava, M; Feder, A; Gallagher, B; Grunebaum, MF; Hock, R; Kissel, N; Lundberg, J; Mann, JJ; Mathew, SJ; McLoughlin, DM; McMillan, R; Murrough, JW; Muthukumaraswamy, S; Papakostas, G; Phillips, JL; Price, RB; Rohac, R; Shiroma, P; Šóš, P; Su, TP; Sumner, R; Tiger, M; Wallace, ML; Wilkinson, ST; Woody, ML; Zarate, CA, 2022) |
| "Psychotic depression is a subtype of major depressive disorder characterized by mood congruent hallucinations and/or delusions." | 6.72 | Ketamine for psychotic depression: An overview of the glutamatergic system and ketamine's mechanisms associated with antidepressant and psychotomimetic effects. ( Cao, B; Cha, DS; Di Vincenzo, JD; Gill, H; Ho, RC; Le, TT; Lee, Y; Lin, K; Lipsitz, O; Lui, LMW; Mansur, RB; McIntyre, RS; Nasri, F; Rodrigues, NB; Rosenblat, JD; Subramaniapillai, M; Teopiz, KM, 2021) |
| "Ketamine is a novel rapid-acting antidepressant with high efficacy in treatment-resistant patients." | 6.72 | Ketamine's effect on inflammation and kynurenine pathway in depression: A systematic review. ( Kopra, E; Mondelli, V; Nikkheslat, N; Pariante, C, 2021) |
| "Ketamine is an anaesthetic medication that acts as an antagonist of the NMDA receptor and has antidepressant potential." | 6.61 | Efficacy of Ketamine in bipolar depression: focus on anhedonia. ( Cubała, WJ; Gałuszko-Węgielnik, M; Górska, N; Jakuszkowiak-Wojten, K; Szarmach, J; Szałach, Ł; Słupski, J; Wiglusz, MS; Wilkowska, A; Włodarczk, A, 2019) |
| "Ketamine has rapid and robust antidepressant effects in depression, while its effects on cognitive measures are less clearly understood." | 5.62 | The potential pro-cognitive effects with intravenous subanesthetic ketamine in adults with treatment-resistant major depressive or bipolar disorders and suicidality. ( Chao, Z; Lan, X; Li, H; McIntyre, RS; Ning, Y; Wang, C; Wu, K; Zheng, W; Zhou, Y, 2021) |
| "Ketamine was well-tolerated, with less than 5% of patients withdrawing due to tolerability concerns." | 5.56 | Safety and tolerability of IV ketamine in adults with major depressive or bipolar disorder: results from the Canadian rapid treatment center of excellence. ( Cha, DS; Gill, H; Ho, R; Kratiuk, K; Lee, Y; Lin, K; Lipsitz, O; Lui, LMW; Mansur, RB; McIntyre, RS; Nasri, F; Rodrigues, NB; Rosenblat, JD; Subramaniapillai, M, 2020) |
| "Ketamine and esketamine, the S-enantiomer of the racemic mixture, have recently generated considerable interest as potential therapeutic agents for Treatment-Resistant Depression (TRD), a complex disorder that includes various psychopathological dimensions and distinct clinical profiles (e." | 5.41 | Rethinking ketamine and esketamine action: Are they antidepressants with mood-stabilizing properties? ( d'Andrea, G; Lorenzo, GD; Mancusi, G; Martinotti, G; McIntyre, RS; Pettorruso, M, 2023) |
| "This study included 127 patients with major depressive disorder or bipolar disorder who received ketamine treatments during a 12-day period." | 5.41 | Sleep improvement is associated with the antidepressant efficacy of repeated-dose ketamine and serum BDNF levels: a post-hoc analysis. ( Lan, X; Liu, W; Ning, Y; Wang, C; Wang, M; Zhan, Y; Zhang, B; Zheng, W; Zhou, Y, 2021) |
| "While the psychiatric benefits of ketamine have been verified through clinical trials, there is limited information about ketamine augmentation in patients with treatment-resistant bipolar depression (TRBPD)." | 5.34 | Transient effects of multi-infusion ketamine augmentation on treatment-resistant depressive symptoms in patients with treatment-resistant bipolar depression - An open-label three-week pilot study. ( Chen, C; Ji, F; Jia, F; Jiang, D; Lin, X; Tian, H; Wang, L; Zhou, C; Zhu, J; Zhuo, C, 2020) |
| "Ketamine induces rapid and robust antidepressant effects, and many patients also describe dissociation, which is associated with antidepressant response." | 5.27 | Features of dissociation differentially predict antidepressant response to ketamine in treatment-resistant depression. ( Ballard, ED; Brutsche, NE; Farmer, C; Jaso, BA; Luckenbaugh, DA; Niciu, MJ; Park, LT; Shovestul, BJ; Zarate, CA, 2018) |
| "The results of this pilot study are inconclusive because they lack power to support an advantage of ketamine anesthesia compared with methohexital in ameliorating depressive symptoms for electroconvulsive therapy." | 5.24 | A Randomized Pilot Study Comparing Ketamine and Methohexital Anesthesia for Electroconvulsive Therapy in Patients With Depression. ( Eads, LA; Golden, K; Han, X; Ray-Griffith, SL; Stowe, ZN, 2017) |
| "To evaluate feasibility and effects of a sub-anesthetic infusion dose of ketamine versus midazolam on suicidal ideation in bipolar depression." | 5.24 | Ketamine versus midazolam in bipolar depression with suicidal thoughts: A pilot midazolam-controlled randomized clinical trial. ( Burke, AK; Cooper, TB; Ellis, SP; Grunebaum, MF; Keilp, JG; Mann, JJ; Marver, JE; Milak, MS; Moitra, VK; Oquendo, MA; Sublette, ME, 2017) |
| " Anhedonia occurs across psychiatric diagnoses and has been associated with specific neural circuits in response to rapid-acting treatments, such as ketamine." | 5.24 | Anhedonia as a clinical correlate of suicidal thoughts in clinical ketamine trials. ( Ameli, R; Ballard, ED; Brutsche, NE; Lally, N; Luckenbaugh, DA; Niciu, MJ; Park, L; Richards, EM; Walls, T; Wills, K; Zarate, CA, 2017) |
| " A statistically significant reduction of depressive symptoms and suicidal ideation after S-ketamine treatment was found." | 5.22 | [Practical aspects of ketamine treatment-Safety, combination treatment and comorbidities]. ( Bauer, M; Findeis, H; Graff, J; Ludwig, V; Mikolas, P; Ritter, P, 2022) |
| "A linear mixed model showed that ketamine significantly lowered fatigue scores compared to placebo from 40 min post-treatment to Day 14 with the exception of Day 7." | 5.22 | An assessment of the anti-fatigue effects of ketamine from a double-blind, placebo-controlled, crossover study in bipolar disorder. ( Luckenbaugh, DA; Machado-Vieira, R; Saligan, LN; Slonena, EE; Zarate, CA, 2016) |
| "Little is known about the antidepressive effects of repeated intravenous ketamine infusions beyond the acute phase of treatment in patients with refractory depression." | 5.22 | Continuation phase intravenous ketamine in adults with treatment-resistant depression. ( Bobo, WV; Frye, MA; Kung, S; Morgan, RJ; Palmer, BA; Rasmussen, KG; Rico, J; Ritter, MJ; Schak, KM; Tye, SJ; Vande Voort, JL, 2016) |
| " Ketamine has been shown to rapidly and robustly decrease symptoms of depression in depressed patients with bipolar disorder." | 5.20 | A single infusion of ketamine improves depression scores in patients with anxious bipolar depression. ( Ionescu, DF; Luckenbaugh, DA; Niciu, MJ; Richards, EM; Zarate, CA, 2015) |
| " Data were examined from 58 patients with major depressive disorder or bipolar disorder enrolled in double-blind, placebo-controlled, crossover studies who received a single infusion of ketamine (0." | 5.20 | Rating depression over brief time intervals with the Hamilton Depression Rating Scale: standard vs. abbreviated scales. ( Ameli, R; Brutsche, NE; Luckenbaugh, DA; Zarate, CA, 2015) |
| " We have previously shown that a single dose of ketamine, a glutamate N-methyl-d-aspartate (NMDA) receptor antagonist, is associated with a rapid reduction in depressive symptom severity and SI in patients with treatment-resistant depression." | 5.20 | Ketamine for rapid reduction of suicidal ideation: a randomized controlled trial. ( Brallier, JW; Charney, DS; Collins, KA; DeWilde, KE; Goodman, WK; Iacoviello, BM; Iosifescu, DV; Kautz, M; Kim, J; Lapidus, KA; Lener, M; Murrough, JW; Perez, AM; Price, RB; Rodriguez, GJ; Soleimani, L; Stern, JB, 2015) |
| "Ketamine, an N-methyl d-aspartate (NMDA) antagonist, has rapid antidepressant effects in depressed subjects with bipolar disorder (BD)." | 5.19 | Neural correlates of rapid antidepressant response to ketamine in bipolar disorder. ( Brutsche, N; Carlson, PJ; Diazgranados, N; Drevets, WC; Herscovitch, P; Ibrahim, L; Luckenbaugh, DA; Nugent, AC; Zarate, CA, 2014) |
| "In this double-blind, randomized, crossover, placebo-controlled study, 15 subjects with DSM-IV bipolar I or II depression maintained on therapeutic levels of lithium or valproate received a single intravenous infusion of either ketamine hydrochloride (." | 5.16 | Replication of ketamine's antidepressant efficacy in bipolar depression: a randomized controlled add-on trial. ( Brutsche, NE; Cravchik, A; Diazgranados, N; Franco-Chaves, J; Ibrahim, L; Liberty, V; Luckenbaugh, DA; Marquardt, CA; Selter, J; Zarate, CA, 2012) |
| "Subjects with major depressive disorder or bipolar disorder referred for ECT treatment of a major depressive episode were randomized to receive thiopental alone or thiopental plus ketamine (0." | 5.16 | Rapid antidepressant effect of ketamine in the electroconvulsive therapy setting. ( Abdallah, CG; Fasula, M; Kelmendi, B; Ostroff, R; Sanacora, G, 2012) |
| " To assess the effects of ketamine and other glutamate receptor modulators in alleviating the acute symptoms of depression in people with bipolar disorder." | 5.12 | Ketamine and other glutamate receptor modulators for depression in adults with bipolar disorder. ( Barnes, A; Cipriani, A; Cowen, PJ; Dean, RL; Geddes, J; Hawton, K; Hurducas, C; Malhi, GS; Marquardt, T; McShane, R; Smith, R; Spyridi, S, 2021) |
| " Many studies have demonstrated the efficacy of ketamine in reducing depressive symptoms in adults with treatment-resistant mood disorders, though few studies utilizing ketamine in youth populations exist." | 5.12 | A systematic review of therapeutic ketamine use in children and adolescents with treatment-resistant mood disorders. ( Kim, S; Rice, TR; Rush, BS, 2021) |
| "The efficacy of ketamine in reducing suicidal ideation (SI) has been previously reported." | 5.12 | The acute antisuicidal effects of single-dose intravenous ketamine and intranasal esketamine in individuals with major depression and bipolar disorders: A systematic review and meta-analysis. ( Carvalho, I; Chen-Li, D; Gill, H; Lee, Y; Lipsitz, O; Lui, LMW; Mansur, RB; McIntyre, RS; Narsi, F; Rodrigues, NB; Rosenblat, JD; Xiong, J, 2021) |
| "The use of ketamine for depression has increased rapidly in the past decades." | 5.12 | Pharmacodynamic Interactions Between Ketamine and Psychiatric Medications Used in the Treatment of Depression: A Systematic Review. ( Bakker, IM; Kamphuis, J; Schoevers, RA; Smith-Apeldoorn, SY; Touw, DJ; Veraart, JKE; Visser, BAE, 2021) |
| "The current meta-analysis examines the effects of ketamine infusion on depressive symptoms over time in major depressive disorder (MDD) and bipolar disorder (BD)." | 4.91 | The use of ketamine as an antidepressant: a systematic review and meta-analysis. ( Coyle, CM; Laws, KR, 2015) |
| " To assess the effects of ketamine and other glutamate receptor modulators in alleviating the acute symptoms of depression in people with bipolar disorder." | 4.91 | Ketamine and other glutamate receptor modulators for depression in bipolar disorder in adults. ( Amit, BH; Brett, D; Caddy, C; Cipriani, A; Diamond, PR; Hamadi, L; Hawton, K; Jochim, J; McCloud, TL; McShane, R; Rendell, JM; Shuttleworth, C, 2015) |
| "This study suggests that ketamine is effective in treatment-resistant bipolar depression and may reduce suicidal ideation and anhedonia." | 4.91 | Efficacy of Ketamine in Bipolar Depression: Systematic Review and Meta-analysis. ( Khosh-Chashm, D; Mascarenhas, SS; Parsaik, AK; Singh, B, 2015) |
| "The electronic database Pubmed, Web of Science and sciencedirect were searched using the keywords: ketamine, N-methyl-d-aspartate receptor antagonist, rapid-acting antidepressant, depression, treatment-resistant depression, bipolar depression, suicidal ideation, electroconvulsive therapy, mechanism of action." | 4.90 | A review of ketamine in affective disorders: current evidence of clinical efficacy, limitations of use and pre-clinical evidence on proposed mechanisms of action. ( Clarke, G; Cryan, JF; Dinan, TG; Naughton, M; O'Leary, OF, 2014) |
| "Although ketamine can rapidly decrease suicidal ideation (SI), its neurobiological mechanism of action remains unclear." | 4.31 | Pre-treatment functional connectivity of the cingulate cortex predicts anti-suicidal effects of serial ketamine infusions. ( Chen, X; Hu, Y; Luo, X; Ning, Y; Wang, M; Yuan, S; Zhang, B; Zhou, Y, 2023) |
| "Depressive symptom severity and the affective index of pain partially mediated improvements in social function after six repeated ketamine treatments among patients with bipolar or unipolar depressive disorder." | 4.31 | Pain mediates the improvement of social functions of repeated intravenous ketamine in patients with unipolar and bipolar depression. ( Gan, Y; Hu, Z; Lan, X; Li, N; Li, W; Liu, H; Ning, Y; Wang, C; Wu, Z; Ye, Y; Zhang, F; Zhou, Y, 2023) |
| "This case presents a female patient diagnosed with both Bipolar Disorder (BD) and Borderline Personality Disorder (BPD) who received intravenous ketamine treatment to alleviate acute depressive symptoms." | 4.31 | Short term ketamine treatment in patient with bipolar disorder with comorbidity with borderline personality disorder: Focus on impulsivity. ( Cubała, WJ; Gałuszko-Węgielnik, M; Jakuszkowiak-Wojten, K; Wilkowska, A, 2023) |
| "This preliminary study found that repeated ketamine infusions appeared to be effective at rapidly ameliorating anhedonia, with similar efficacy in MDD and BD." | 4.12 | Comparative effectiveness of repeated ketamine infusions in treating anhedonia in bipolar and unipolar depression. ( Gu, LM; Lan, XF; Ning, YP; Sun, CH; Wang, CY; Zhang, B; Zheng, W; Zhou, YL, 2022) |
| "Although preliminary, present findings suggest that repeated subcutaneous esketamine infusions are effective for the treatment of anhedonia in both unipolar and bipolar depressed patients." | 4.02 | Comparative effectiveness of esketamine in the treatment of anhedonia in bipolar and unipolar depression. ( Barbosa, MG; Del-Porto, JA; Delfino, RS; Fava, VAR; Lacerda, ALT; Lucchese, AC; Magalhães, E; Nakahira, C; Sant, LCD; Sarin, LM; Steglich, MS; Surjan, J; Tuena, MA, 2021) |
| "Patients with TRD and prominent anxiety receiving IV ketamine exhibited a significant reduction in depressive, SI and anxiety symptoms." | 4.02 | The effectiveness of intravenous ketamine in adults with treatment-resistant major depressive disorder and bipolar disorder presenting with prominent anxiety: Results from the Canadian Rapid Treatment Center of Excellence. ( Gill, H; Ho, R; Kratiuk, K; Lee, Y; Lipsitz, O; Lui, LM; Mansur, RB; McIntyre, RS; Nasri, F; Rodrigues, NB; Rosenblat, JD; Subramaniapillai, M; Teopiz, K, 2021) |
| "We evaluated the effects of repeated subanesthetic ketamine infusions on suicidal ideation (SI) in patients with major depression." | 4.02 | Subanesthetic ketamine infusions for suicide ideation in patients with bipolar and unipolar treatment refractory depression. ( Anjum, MR; Chandrasena, R; Fairbairn, J; Hawken, ER; Kang, MJY; Kulcar, E; Vazquez, GH, 2021) |
| " Herein, we investigated whether pre-treatment functioning in outpatients with treatment-resistant depression (TRD) moderates response to intravenous (IV) ketamine." | 4.02 | Does pre-treatment functioning influence response to intravenous ketamine in adults with treatment-resistant depression? ( Cha, DS; Gill, H; Ho, RC; Kratiuk, K; Lee, Y; Lin, K; Lipsitz, O; Lui, LMW; Mansur, RB; McIntyre, RS; Nasri, F; Rodrigues, NB; Rosenblat, JD; Subramaniapillai, M; Teopiz, KM, 2021) |
| "To identify a meaningful change threshold (MCT) in depression outcomes in adults with treatment-resistant major depressive disorder (MDD) or bipolar disorder (BD) receiving intravenous ketamine treatment at a community-based mood disorders center." | 4.02 | The meaningful change threshold as measured by the 16-item quick inventory of depressive symptomatology in adults with treatment-resistant major depressive and bipolar disorder receiving intravenous ketamine. ( Gill, H; Ho, RC; Jones, BDM; Kratiuk, K; Lee, Y; Ling, R; Lipsitz, O; Lui, LMW; Mansur, RB; McIntyre, RS; Nasri, F; Rodrigues, NB; Rosenblat, JD; Subramaniapillai, M; Teopiz, KM, 2021) |
| "To determine the effectiveness of intravenous (IV) ketamine on anxiety, irritability, agitation, and suicidality, in adults with treatment-resistant major depressive disorder (MDD) or bipolar disorder (BD)." | 3.96 | The effectiveness of ketamine on anxiety, irritability, and agitation: Implications for treating mixed features in adults with major depressive or bipolar disorder. ( Cha, DS; Fagiolini, A; Gill, H; Ho, R; Kratiuk, K; Lee, Y; Lin, K; Lipsitz, O; Malhi, GS; Mansur, RB; McIntyre, RS; Nasri, F; Rodrigues, NB; Rosenblat, JD; Subramaniapillai, M; Suppes, T; Vinberg, M, 2020) |
| "The effectiveness, tolerability, and safety of intravenous (IV) ketamine in adults with treatment resistant depression (TRD) receiving care in real-word settings is insufficiently characterized." | 3.96 | The effectiveness of repeated intravenous ketamine on depressive symptoms, suicidal ideation and functional disability in adults with major depressive disorder and bipolar disorder: Results from the Canadian Rapid Treatment Center of Excellence. ( Abrishami, A; Arekapudi, AK; Brietzke, E; Carvalho, IP; Chau, EH; Gill, H; Kratiuk, K; Lee, Y; Lipsitz, O; Lui, LMW; Majeed, A; Mansur, RB; McIntyre, RS; Nasri, F; Phan, L; Rodrigues, NB; Rosenblat, JD; Senyk, O; Siegel, A; Subramaniapillai, M; Szpejda, W, 2020) |
| "After adjusting for age, sex, primary diagnosis, concomitant medication, body mass index, and baseline depression severity, there was a statistically significant reduction in symptoms of anhedonia with IV ketamine treatment (F (2, 235." | 3.96 | Changes in symptoms of anhedonia in adults with major depressive or bipolar disorder receiving IV ketamine: Results from the Canadian Rapid Treatment Center of Excellence. ( Cha, DS; Gill, H; Ho, R; Kratiuk, K; Lee, Y; Lin, K; Lipsitz, O; Majeed, A; Mansur, RB; McIntyre, RS; Nasri, F; Phan, L; Rodrigues, NB; Rosenblat, JD; Subramaniapillai, M, 2020) |
| " Previous studies found that ketamine intervention could rapidly reduce suicidal ideation in depression." | 3.91 | A preliminary study of anti-suicidal efficacy of repeated ketamine infusions in depression with suicidal ideation. ( Chen, L; Li, H; Li, M; Li, MD; Liu, W; Ning, Y; Walter, M; Wang, C; Yu, L; Zhan, Y; Zhang, B; Zheng, W; Zhou, Y, 2019) |
| "No pharmacological treatments exist for active suicidal ideation (SI), but the glutamatergic modulator ketamine elicits rapid changes in SI." | 3.88 | Characterizing the course of suicidal ideation response to ketamine. ( Ballard, ED; Farmer, CA; Kadriu, B; Machado-Vieira, R; Niciu, MJ; Park, L; Richards, E; Yarrington, JS; Yuan, P; Zarate, CA, 2018) |
| "Ketamine has rapid antidepressant effects on treatment-resistant depression, but the biological mechanism underpinning this effect is less clear." | 3.88 | Antidepressant effect of repeated ketamine administration on kynurenine pathway metabolites in patients with unipolar and bipolar depression. ( Chen, L; Li, H; Li, M; Liu, W; Ning, Y; Wang, C; Zhan, Y; Zheng, W; Zhou, Y, 2018) |
| "Ketamine is a standard anaesthetic drug that has been studied as a possible treatment for acute suicidal ideation." | 3.85 | Use of ketamine for acute suicidal ideation in a patient with chronic pain on prescribed cannabinoids. ( Bigman, D; Bobrin, B; Kunaparaju, S, 2017) |
| "Data from 108 treatment-resistant inpatients meeting criteria for major depressive disorder and bipolar disorder who received a single subanesthetic ketamine infusion were analyzed." | 3.80 | Do the dissociative side effects of ketamine mediate its antidepressant effects? ( Brutsche, NE; Guevara, S; Ionescu, DF; Luckenbaugh, DA; Niciu, MJ; Nolan, NM; Richards, EM; Zarate, CA, 2014) |
| "Despite this, there are few effective treatments for BD depression, with only a handful of atypical anti-psychotics and inconsistent evidence for traditional mood stabilizing agents." | 3.01 | New Pharmacologic Approaches to the Treatment of Bipolar Depression. ( Chakrabarty, T; DuBois, A; Keramatian, K; Saraf, G; Yatham, LN, 2023) |
| " Older age, hypertension, large ketamine dosage and dissociative symptoms may predict increased ketamine-induced cardiovascular effects." | 3.01 | Cardiovascular effects of repeated subanaesthetic ketamine infusion in depression. ( Lan, XF; Liu, WJ; Ning, YP; Wang, CY; Weng, SY; Zheng, W; Zhou, YL, 2021) |
| "Ketamine has proven to have rapid, robust antidepressant effects on treatment-resistant depression." | 2.87 | Neurocognitive effects of six ketamine infusions and the association with antidepressant response in patients with unipolar and bipolar depression. ( Chen, L; Li, H; Li, M; Liu, W; Ning, Y; Wang, C; Zhan, Y; Zheng, W; Zhou, Y, 2018) |
| "Depression is disabling and highly prevalent." | 2.82 | International pooled patient-level meta-analysis of ketamine infusion for depression: In search of clinical moderators. ( Abdallah, CG; Ballard, ED; Baumeister, A; Blier, P; Charney, DS; Chen, MH; Deakin, W; Fava, M; Feder, A; Gallagher, B; Grunebaum, MF; Hock, R; Kissel, N; Lundberg, J; Mann, JJ; Mathew, SJ; McLoughlin, DM; McMillan, R; Murrough, JW; Muthukumaraswamy, S; Papakostas, G; Phillips, JL; Price, RB; Rohac, R; Shiroma, P; Šóš, P; Su, TP; Sumner, R; Tiger, M; Wallace, ML; Wilkinson, ST; Woody, ML; Zarate, CA, 2022) |
| "Twenty-nine subjects with bipolar depression received a double-blind, randomized, subanesthetic dose (." | 2.80 | Shank3 as a potential biomarker of antidepressant response to ketamine and its neural correlates in bipolar depression. ( Luckenbaugh, DA; Lukkahati, N; Machado-Vieira, R; Niciu, MJ; Nugent, AC; Ortiz, R; Saligan, LN; Zarate, CA, 2015) |
| "To construct a population pharmacokinetic (popPK) model for ketamine (Ket), norketamine (norKet), dehydronorketamine (DHNK), hydroxynorketamine (2S,6S;2R,6R)-HNK) and hydroxyketamine (HK) in patients with treatment-resistant bipolar depression." | 2.77 | Simultaneous population pharmacokinetic modelling of ketamine and three major metabolites in patients with treatment-resistant bipolar depression. ( Brutsche, NE; Ibrahim, L; Luckenbaugh, DA; Mager, DE; Moaddel, R; Venkata, SL; Wainer, IW; Zarate, CA; Zhao, X, 2012) |
| "Ketamine was generally well tolerated; the most common adverse effect was dissociative symptoms, only at the 40-minute point." | 2.75 | A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression. ( Brutsche, NE; Diazgranados, N; Ibrahim, L; Kammerer, WA; Khalife, S; Kronstein, P; Luckenbaugh, DA; Machado-Vieira, R; Manji, HK; Newberg, A; Quezado, Z; Salvadore, G; Zarate, CA, 2010) |
| "Psychotic depression is a subtype of major depressive disorder characterized by mood congruent hallucinations and/or delusions." | 2.72 | Ketamine for psychotic depression: An overview of the glutamatergic system and ketamine's mechanisms associated with antidepressant and psychotomimetic effects. ( Cao, B; Cha, DS; Di Vincenzo, JD; Gill, H; Ho, RC; Le, TT; Lee, Y; Lin, K; Lipsitz, O; Lui, LMW; Mansur, RB; McIntyre, RS; Nasri, F; Rodrigues, NB; Rosenblat, JD; Subramaniapillai, M; Teopiz, KM, 2021) |
| "Ketamine was reasonably well tolerated; however, 2 participants (1 receiving ketamine and 1 receiving placebo) developed manic symptoms." | 2.72 | Ketamine for Bipolar Depression: A Systematic Review. ( Bahji, A; Vazquez, GH; Zarate, CA, 2021) |
| "Ketamine is a novel rapid-acting antidepressant with high efficacy in treatment-resistant patients." | 2.72 | Ketamine's effect on inflammation and kynurenine pathway in depression: A systematic review. ( Kopra, E; Mondelli, V; Nikkheslat, N; Pariante, C, 2021) |
| " The literature shows that treatment with ketamine is efficacious and safe, and the majority of adverse drug reactions are mild and tend to mostly disappear within 30 min to 2 h of ketamine administration." | 2.66 | Safety and Tolerability of Ketamine Use in Treatment-Resistant Bipolar Depression Patients with Regard to Central Nervous System Symptomatology: Literature Review and Analysis. ( Cubała, WJ; Włodarczyk, A, 2020) |
| " We excluded studies with bipolar depression or with repeated dosing and no single-dose phase." | 2.66 | The relationship between subjective effects induced by a single dose of ketamine and treatment response in patients with major depressive disorder: A systematic review. ( Kosten, TR; Mathai, DS; Meyer, MJ; Storch, EA, 2020) |
| "20 (depending on the dosing regimen used); p ≤ 0." | 2.66 | Efficacy of single and repeated administration of ketamine in unipolar and bipolar depression: a meta-analysis of randomized clinical trials. ( Brzostek, T; Kawalec, P; Kryst, J; Lasoń, W; Mitoraj, AM; Pilc, A, 2020) |
| "Ketamine has been receiving increasing attention as an interventional treatment modality in psychiatry, especially among refractory conditions, including major depressive disorder." | 2.66 | Efficacy and safety of ketamine in the management of anxiety and anxiety spectrum disorders: a review of the literature. ( Banov, MD; Dunn, T; Szabo, ST; Young, JR, 2020) |
| "Ketamine is an anaesthetic medication that acts as an antagonist of the NMDA receptor and has antidepressant potential." | 2.61 | Efficacy of Ketamine in bipolar depression: focus on anhedonia. ( Cubała, WJ; Gałuszko-Węgielnik, M; Górska, N; Jakuszkowiak-Wojten, K; Szarmach, J; Szałach, Ł; Słupski, J; Wiglusz, MS; Wilkowska, A; Włodarczk, A, 2019) |
| "Ketamine is a racemic mixture comprising equal parts of (R)-ketamine (or arketamine) and (S)-ketamine (or esketamine)." | 2.61 | Rapid-acting antidepressant ketamine, its metabolites and other candidates: A historical overview and future perspective. ( Hashimoto, K, 2019) |
| "Ketamine treatment showed acute effectiveness in another 7 cases, especially in terms of reduction of suicidal ideation, albeit without significant long-term antidepressant effect." | 2.58 | Is Ketamine the Future Clozapine for Depression? A Case Series and Literature Review on Maintenance Ketamine in Treatment-resistant Depression With Suicidal Behavior. ( Chan, LF; Chong, BTW; Eu, CL; Kahn, DA; Loo, JL; Loo, TH; Maniam, T; Ng, YP; Shahidii Kadir, Z; Sharip, S; Soh, SY; Wong, VCW, 2018) |
| "Subjects were diagnosed with either major depressive disorder (MDD) or bipolar depression." | 2.55 | Symptomatology and predictors of antidepressant efficacy in extended responders to a single ketamine infusion. ( Luckenbaugh, DA; Niciu, MJ; Pennybaker, SJ; Zarate, CA, 2017) |
| "Ketamine was always superior to placebo." | 2.55 | Administration of ketamine for unipolar and bipolar depression. ( Bartova, L; Carlberg, L; Gryglewski, G; Kasper, S; Kraus, C; Lanzenberger, R; Papageorgiou, K; Popovic, A; Rabl, U; Rybakowski, JK; Spies, M; Vanicek, T; Willeit, M; Winkler, D, 2017) |
| " Secondary outcomes included response, remission, all-cause discontinuation and adverse effects." | 2.53 | Single-dose infusion ketamine and non-ketamine N-methyl-d-aspartate receptor antagonists for unipolar and bipolar depression: a meta-analysis of efficacy, safety and time trajectories. ( Bauer, M; Chawla, JM; Correll, CU; Hagi, K; Kane, JM; Kishimoto, T; Zarate, CA, 2016) |
| "Ketamine's efficacy was confirmed in MDD (resistant to previous pharmacological treatments or not) (SMD = -0." | 2.50 | Ketamine administration in depressive disorders: a systematic review and meta-analysis. ( Abbar, M; Boyer, L; Brittner, M; Courtet, P; Fond, G; Lançon, C; Leboyer, M; Loundou, A; Macgregor, A; Micoulaud-Franchi, JA; Rabu, C; Richieri, R; Roger, M, 2014) |
| "Ketamine was proven to have short-term antidepressant effects." | 1.72 | Long-term outcomes of repeated ketamine infusions in patients with unipolar and bipolar depression: A naturalistic follow-up study. ( Lan, X; Li, W; Liu, H; Liu, W; McIntyre, RS; Ning, Y; Wang, C; Wu, K; Ye, Y; Zhang, F; Zhang, Z; Zhou, Y, 2022) |
| "Esketamine was safe and well tolerated." | 1.72 | Efficacy and Safety of Subcutaneous Esketamine in the Treatment of Suicidality in Major Depressive Disorder and Bipolar Depression. ( Abdo, GL; Barbosa, MG; de Oliveira Cerqueira, R; Del Porto, JA; Del Sant, LC; Delfino, RS; Fava, VAR; Grossi, JD; Lacerda, ALT; Lucchese, AC; Magalhães, E; Nakahira, C; Sarin, LM; Steglich, MS; Surjan, J; Tuena, MA, 2022) |
| "Ketamine has rapid and robust antidepressant effects in depression, while its effects on cognitive measures are less clearly understood." | 1.62 | The potential pro-cognitive effects with intravenous subanesthetic ketamine in adults with treatment-resistant major depressive or bipolar disorders and suicidality. ( Chao, Z; Lan, X; Li, H; McIntyre, RS; Ning, Y; Wang, C; Wu, K; Zheng, W; Zhou, Y, 2021) |
| "Ketamine has been demonstrated to have robust and rapid antidepressant effects, and few studies have focused on the relationship between insomnia and the efficacy of ketamine." | 1.56 | Baseline insomnia as a predictor of antidepressant efficacy to repeated intravenous ketamine for unipolar and bipolar depression: A preliminary study. ( Chen, L; Lan, X; Li, H; Li, M; Liu, W; Ning, Y; Wang, C; Zhan, Y; Zhang, B; Zheng, W; Zhou, Y, 2020) |
| "Ketamine was well-tolerated, with less than 5% of patients withdrawing due to tolerability concerns." | 1.56 | Safety and tolerability of IV ketamine in adults with major depressive or bipolar disorder: results from the Canadian rapid treatment center of excellence. ( Cha, DS; Gill, H; Ho, R; Kratiuk, K; Lee, Y; Lin, K; Lipsitz, O; Lui, LMW; Mansur, RB; McIntyre, RS; Nasri, F; Rodrigues, NB; Rosenblat, JD; Subramaniapillai, M, 2020) |
| "Ketamine has shown rapid antidepressant effects in depressed patients." | 1.56 | A preliminary study of adjunctive ketamine for treatment-resistant bipolar depression. ( Lan, XF; Liu, WJ; Ning, YP; Wang, CY; Zhan, YN; Zhang, B; Zheng, W; Zhou, YL, 2020) |
| "Inpatients with major depressive disorder (n = 76) or bipolar depression (n = 43) were participating in clinical ketamine trials." | 1.48 | Parsing the heterogeneity of depression: An exploratory factor analysis across commonly used depression rating scales. ( Ballard, ED; Farmer, CA; Kadriu, B; Lally, N; Lener, MS; Machado-Vieira, R; Niciu, MJ; Park, L; Williams, D; Yarrington, JS; Zarate, CA, 2018) |
| "Six ketamine infusions were safe and effective in patients with unipolar and bipolar depression." | 1.48 | Rapid and longer-term antidepressant effects of repeated-dose intravenous ketamine for patients with unipolar and bipolar depression. ( Chen, LJ; Li, HQ; Li, MD; Liu, WJ; Ning, YP; Wang, CY; Zhan, YN; Zheng, W; Zhou, YL, 2018) |
| "The ketamine-treated sample included 157 unrelated European subjects with major depressive disorder (MDD) or bipolar disorder (BD)." | 1.48 | Exploratory genome-wide association analysis of response to ketamine and a polygenic analysis of response to scopolamine in depression. ( Akula, N; Charney, DS; Drevets, W; Furey, M; Grunebaum, M; Guo, W; Henter, I; Kadriu, B; Machado-Vieira, R; Mann, JJ; Mathew, S; McMahon, FJ; Merikangas, K; Murrough, JW; Oquendo, MA; Shugart, YY; Yuan, P; Zarate, CA, 2018) |
| "Edaravone (18 mg/kg) treatment did not prevent hyperlocomotion in the mania model induced with ketamine in rats, but lithium chloride (47." | 1.43 | The effects of edaravone in ketamine-induced model of mania in rats. ( Altun, İK; Alver, A; Arslan, FC; Gedikli, Ö; İnce, İ; Özkorumak, E; Tiryaki, A; Yıldırım, M, 2016) |
| "Ketamine treatment decreased the hippocampal membrane level of phosphorylated PSD-95 on Thr-19, the target of GSK3 that promotes AMPA receptor internalization." | 1.43 | Ketamine-induced inhibition of glycogen synthase kinase-3 contributes to the augmentation of α-amino-3-hydroxy-5-methylisoxazole-4-propionic acid (AMPA) receptor signaling. ( Amadei, C; Beurel, E; Downey, K; Grieco, SF; Jope, RS, 2016) |
| "ketamine treatment induced hyperlocomotion and oxidative damage in cerebral cortex, hippocampus and striatum such as an increase in lipid peroxidation and a decrease in the antioxidant enzymes activities (superoxide dismutase, catalase e glutatione peroxidase)." | 1.43 | Preventive effects of blueberry extract on behavioral and biochemical dysfunctions in rats submitted to a model of manic behavior induced by ketamine. ( Braganhol, E; Chaves, VC; Debom, G; do Couto, CA; Gazal, M; Ghisleni, GC; Kaster, MP; Lencina, C; Mattos, B; Reginatto, FH; Soares, MS; Spanevello, RM; Stefanello, F; Tavares, R, 2016) |
| " The combined ketamine and transcranial magnetic stimulation treatment was administered a total of 24 times over five months, with his ketamine dosage increased from 50mg at the first treatment to 600 mg by the last." | 1.42 | Ketamine and transcranial magnetic stimulation treatment for bipolar II disorder: a case report. ( Best, SR; Griffin, BP; Pavel, DG, 2015) |
| "Like ketamine, it is an NMDA receptor antagonist." | 1.40 | The utility of the combination of dextromethorphan and quinidine in the treatment of bipolar II and bipolar NOS. ( Kelly, TF; Lieberman, DZ, 2014) |
| "Ketamine (Ketalar®) is an anesthetic agent derived from the hallucinogenic drug phencyclidine (PCP)." | 1.39 | Ketamine for the treatment of depression. ( Howland, RH, 2013) |
| " Sublingual administration of ketamine renders better bioavailability (~30%) and less conversion to norketamine than oral administration." | 1.39 | Antidepressant, mood stabilizing and procognitive effects of very low dose sublingual ketamine in refractory unipolar and bipolar depression. ( Bisol, LW; Lara, DR; Munari, LR, 2013) |
| "Ketamine has rapid antidepressant effects lasting as long as 1 week in patients with major depressive disorder (MDD) and bipolar depression (BD)." | 1.38 | Relationship of ketamine's plasma metabolites with response, diagnosis, and side effects in major depression. ( Brutsche, N; Laje, G; Luckenbaugh, DA; Moaddel, R; Ramamoorthy, A; Venkata, SL; Wainer, IW; Zarate, CA, 2012) |
| "Ketamine has rapid antidepressant properties in major depressive disorder (MDD) as well as bipolar depression." | 1.38 | Family history of alcohol dependence and antidepressant response to an N-methyl-D-aspartate antagonist in bipolar depression. ( Brutsche, N; Cassarly, C; Franco-Chaves, J; Ibrahim, L; Luckenbaugh, DA; Marquardt, CA; Mathews, D; Zarate, CA, 2012) |
| "Ketamine was well tolerated and prolonged seizure duration overall, but particularly in those who had a seizure duration shorter than 25 seconds with methohexital at the maximum available stimulus intensity." | 1.32 | Comparison of seizure duration, ictal EEG, and cognitive effects of ketamine and methohexital anesthesia with ECT. ( Coffey, CE; Dean, MD; Falcone, G; Krystal, AD; Lindahl, VH; Tramontozzi, LA; Weiner, RD, 2003) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (0.56) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (1.11) | 29.6817 |
| 2010's | 106 (58.89) | 24.3611 |
| 2020's | 71 (39.44) | 2.80 |
| Authors | Studies |
|---|---|
| Singh, B | 7 |
| Vande Voort, JL | 10 |
| Kung, S | 4 |
| Dean, RL | 1 |
| Marquardt, T | 1 |
| Hurducas, C | 1 |
| Spyridi, S | 1 |
| Barnes, A | 1 |
| Smith, R | 1 |
| Cowen, PJ | 1 |
| McShane, R | 2 |
| Hawton, K | 2 |
| Malhi, GS | 2 |
| Geddes, J | 1 |
| Cipriani, A | 2 |
| Mathai, DS | 2 |
| McCathern, AG | 1 |
| Guzick, AG | 1 |
| Schneider, SC | 1 |
| Weinzimmer, SA | 1 |
| Cepeda, SL | 1 |
| Garcia-Romeu, A | 1 |
| Storch, EA | 2 |
| Zhou, Y | 11 |
| Wang, C | 8 |
| Lan, X | 5 |
| Zheng, W | 10 |
| Li, H | 5 |
| Chao, Z | 1 |
| Wu, K | 2 |
| McIntyre, RS | 18 |
| Ning, Y | 10 |
| Le, TT | 1 |
| Di Vincenzo, JD | 1 |
| Teopiz, KM | 3 |
| Lee, Y | 13 |
| Cha, DS | 6 |
| Lui, LMW | 6 |
| Rodrigues, NB | 12 |
| Ho, RC | 3 |
| Cao, B | 1 |
| Lin, K | 6 |
| Nasri, F | 11 |
| Gill, H | 12 |
| Lipsitz, O | 12 |
| Subramaniapillai, M | 11 |
| Mansur, RB | 13 |
| Rosenblat, JD | 13 |
| Mouwen, A | 1 |
| Walsh, S | 1 |
| Andrade, C | 2 |
| Li, W | 2 |
| Liu, W | 6 |
| Zhang, Z | 1 |
| Zhang, F | 2 |
| Ye, Y | 2 |
| Liu, H | 2 |
| Gu, LM | 1 |
| Sun, CH | 1 |
| Zhou, YL | 4 |
| Wang, CY | 4 |
| Lan, XF | 3 |
| Zhang, B | 7 |
| Ning, YP | 4 |
| Vaccarino, SR | 1 |
| Adamsahib, F | 1 |
| Milev, RV | 1 |
| Parikh, SV | 1 |
| Lam, RW | 1 |
| Blier, P | 2 |
| Kennedy, SH | 1 |
| Ladha, KS | 1 |
| Bhat, V | 1 |
| Karakatsoulis, GN | 1 |
| Tsapakis, EM | 1 |
| Fountoulakis, KN | 1 |
| Bourla, A | 1 |
| Ferreri, F | 1 |
| Baudry, T | 1 |
| Panizzi, V | 1 |
| Adrien, V | 1 |
| Mouchabac, S | 1 |
| Findeis, H | 1 |
| Ludwig, V | 1 |
| Mikolas, P | 1 |
| Graff, J | 1 |
| Bauer, M | 2 |
| Ritter, P | 1 |
| Frye, MA | 6 |
| Shiroma, PR | 1 |
| Velit-Salazar, MR | 1 |
| Vorobyov, Y | 1 |
| Dmitrzak-Weglarz, M | 1 |
| Tyszkiewicz-Nwafor, M | 1 |
| Rybakowski, F | 1 |
| Permoda-Pachuta, A | 1 |
| Surjan, J | 5 |
| Grossi, JD | 4 |
| Del Porto, JA | 4 |
| Delfino, RS | 5 |
| de Oliveira Cerqueira, R | 1 |
| Lucchese, AC | 2 |
| Magalhães, E | 2 |
| Del Sant, LC | 1 |
| Tuena, MA | 2 |
| Nakahira, C | 2 |
| Fava, VAR | 2 |
| Steglich, MS | 2 |
| Abdo, GL | 1 |
| Barbosa, MG | 2 |
| Sarin, LM | 2 |
| Lacerda, ALT | 7 |
| Price, RB | 2 |
| Kissel, N | 1 |
| Baumeister, A | 1 |
| Rohac, R | 1 |
| Woody, ML | 1 |
| Ballard, ED | 10 |
| Zarate, CA | 33 |
| Deakin, W | 1 |
| Abdallah, CG | 2 |
| Feder, A | 1 |
| Charney, DS | 3 |
| Grunebaum, MF | 3 |
| Mann, JJ | 3 |
| Mathew, SJ | 2 |
| Gallagher, B | 1 |
| McLoughlin, DM | 1 |
| Murrough, JW | 4 |
| Muthukumaraswamy, S | 1 |
| McMillan, R | 1 |
| Sumner, R | 1 |
| Papakostas, G | 1 |
| Fava, M | 2 |
| Hock, R | 1 |
| Phillips, JL | 1 |
| Shiroma, P | 1 |
| Šóš, P | 2 |
| Su, TP | 2 |
| Chen, MH | 2 |
| Tiger, M | 1 |
| Lundberg, J | 1 |
| Wilkinson, ST | 3 |
| Wallace, ML | 1 |
| Wilkowska, A | 5 |
| Cubała, WJ | 6 |
| Martinotti, G | 2 |
| Dell'Osso, B | 1 |
| Di Lorenzo, G | 1 |
| Maina, G | 1 |
| Bertolino, A | 1 |
| Clerici, M | 1 |
| Barlati, S | 1 |
| Rosso, G | 1 |
| Di Nicola, M | 1 |
| Marcatili, M | 1 |
| d'Andrea, G | 2 |
| Cavallotto, C | 1 |
| Chiappini, S | 1 |
| De Filippis, S | 1 |
| Nicolò, G | 1 |
| De Fazio, P | 1 |
| Andriola, I | 1 |
| Zanardi, R | 1 |
| Nucifora, D | 1 |
| Di Mauro, S | 1 |
| Bassetti, R | 1 |
| Pettorruso, M | 2 |
| Sensi, SL | 1 |
| di Giannantonio, M | 1 |
| Vita, A | 1 |
| Riva-Posse, P | 2 |
| Pazdernik, VM | 1 |
| Tye, SJ | 3 |
| Lorenzo, GD | 1 |
| Mancusi, G | 1 |
| Hashimoto, K | 4 |
| Chaki, S | 1 |
| Chen, X | 2 |
| Yuan, S | 1 |
| Luo, X | 1 |
| Wang, M | 2 |
| Hu, Y | 2 |
| Wu, Z | 1 |
| Gan, Y | 1 |
| Li, N | 1 |
| Hu, Z | 1 |
| Keramatian, K | 1 |
| Chakrabarty, T | 1 |
| DuBois, A | 1 |
| Saraf, G | 1 |
| Yatham, LN | 2 |
| Gonçalves, MAS | 1 |
| Leite, TRA | 1 |
| Júnior, EAB | 1 |
| Araújo, GAC | 1 |
| Bisol, LW | 2 |
| Gomes de Matos E Souza, F | 1 |
| van den Brink, W | 1 |
| van Amsterdam, J | 1 |
| Vázquez, GH | 4 |
| Baldessarini, RJ | 2 |
| Gałuszko-Węgielnik, M | 2 |
| Jakuszkowiak-Wojten, K | 2 |
| Johnston, JN | 1 |
| Kadriu, B | 4 |
| Kraus, C | 2 |
| Henter, ID | 2 |
| Bandeira, ID | 1 |
| Leal, GC | 1 |
| Correia-Melo, FS | 1 |
| Souza-Marques, B | 2 |
| Silva, SS | 1 |
| Lins-Silva, DH | 2 |
| Mello, RP | 1 |
| Vieira, F | 2 |
| Dorea-Bandeira, I | 1 |
| Faria-Guimarães, D | 1 |
| Carneiro, B | 1 |
| Caliman-Fontes, AT | 1 |
| Kapczinski, F | 1 |
| Miranda-Scippa, Â | 1 |
| Quarantini, LC | 2 |
| Cheng, CM | 1 |
| Gueorguieva, R | 2 |
| Lin, WC | 1 |
| Li, CT | 1 |
| Hong, CJ | 1 |
| Tu, PC | 1 |
| Bai, YM | 1 |
| Tsai, SJ | 1 |
| Krystal, JH | 2 |
| Wiglusz, MS | 1 |
| Słupski, J | 1 |
| Szałach, Ł | 1 |
| Włodarczk, A | 1 |
| Górska, N | 1 |
| Szarmach, J | 1 |
| Bobo, WV | 3 |
| Rasmussen, KG | 2 |
| Stoppel, CJ | 1 |
| Rico, JA | 1 |
| Schak, KM | 2 |
| Biernacka, JM | 1 |
| Włodarczyk, A | 1 |
| Meyer, MJ | 1 |
| Kosten, TR | 1 |
| Kryst, J | 1 |
| Kawalec, P | 1 |
| Mitoraj, AM | 1 |
| Pilc, A | 1 |
| Lasoń, W | 1 |
| Brzostek, T | 1 |
| Zhan, Y | 5 |
| Chen, L | 4 |
| Li, M | 5 |
| Kim, S | 1 |
| Rush, BS | 1 |
| Rice, TR | 1 |
| Vinberg, M | 1 |
| Kratiuk, K | 10 |
| Fagiolini, A | 1 |
| Suppes, T | 1 |
| Ho, R | 5 |
| Kavalali, ET | 1 |
| Monteggia, LM | 1 |
| Zhuo, C | 1 |
| Ji, F | 1 |
| Tian, H | 1 |
| Wang, L | 1 |
| Jia, F | 1 |
| Jiang, D | 1 |
| Chen, C | 1 |
| Zhou, C | 1 |
| Lin, X | 2 |
| Zhu, J | 1 |
| Liu, WJ | 3 |
| Zhan, YN | 2 |
| Majeed, A | 3 |
| Senyk, O | 1 |
| Phan, L | 2 |
| Carvalho, IP | 1 |
| Siegel, A | 1 |
| Brietzke, E | 1 |
| Arekapudi, AK | 1 |
| Abrishami, A | 1 |
| Chau, EH | 1 |
| Szpejda, W | 1 |
| Weng, SY | 1 |
| Fornaro, M | 1 |
| Carvalho, AF | 2 |
| Fusco, A | 1 |
| Anastasia, A | 1 |
| Solmi, M | 1 |
| Berk, M | 2 |
| Sim, K | 1 |
| Vieta, E | 2 |
| de Bartolomeis, A | 1 |
| Munkholm, K | 1 |
| Jørgensen, KJ | 1 |
| Del-Porto, JA | 1 |
| Sant, LCD | 1 |
| Lui, LM | 1 |
| Teopiz, K | 1 |
| Kang, MJY | 1 |
| Kulcar, E | 1 |
| Chandrasena, R | 1 |
| Anjum, MR | 1 |
| Fairbairn, J | 1 |
| Hawken, ER | 1 |
| Xiong, J | 1 |
| Chen-Li, D | 2 |
| Carvalho, I | 1 |
| Narsi, F | 1 |
| Gao, TH | 1 |
| Ni, RJ | 1 |
| Liu, S | 1 |
| Tian, Y | 1 |
| Wei, J | 1 |
| Zhao, L | 1 |
| Wang, Q | 1 |
| Ni, P | 1 |
| Ma, X | 1 |
| Li, T | 1 |
| Zhan, Z | 1 |
| Wang, X | 1 |
| Chen, Q | 1 |
| Xiao, Z | 1 |
| Ozerdem, A | 1 |
| McDonald, WM | 1 |
| Jesus-Nunes, AP | 1 |
| Greenway, KT | 1 |
| Garel, N | 1 |
| Goyette, N | 1 |
| Turecki, G | 1 |
| Richard-Devantoy, S | 1 |
| Bahji, A | 1 |
| Bhatt, K | 1 |
| Yoo, J | 1 |
| Bridges, A | 1 |
| Lee, JG | 1 |
| Wang, A | 1 |
| Veraart, JKE | 1 |
| Smith-Apeldoorn, SY | 1 |
| Bakker, IM | 1 |
| Visser, BAE | 1 |
| Kamphuis, J | 1 |
| Schoevers, RA | 1 |
| Touw, DJ | 1 |
| Kopra, E | 1 |
| Mondelli, V | 1 |
| Pariante, C | 1 |
| Nikkheslat, N | 1 |
| Ling, R | 1 |
| Jones, BDM | 1 |
| Anderson, IM | 1 |
| Blamire, A | 1 |
| Branton, T | 1 |
| Clark, R | 1 |
| Downey, D | 1 |
| Dunn, G | 1 |
| Easton, A | 1 |
| Elliott, R | 1 |
| Elwell, C | 1 |
| Hayden, K | 1 |
| Holland, F | 1 |
| Karim, S | 1 |
| Loo, C | 1 |
| Lowe, J | 1 |
| Nair, R | 1 |
| Oakley, T | 1 |
| Prakash, A | 1 |
| Sharma, PK | 1 |
| Williams, SR | 1 |
| McAllister-Williams, RH | 1 |
| Mandyam, MC | 1 |
| Ahuja, NK | 1 |
| Ray-Griffith, SL | 1 |
| Eads, LA | 1 |
| Han, X | 1 |
| Golden, K | 1 |
| Stowe, ZN | 1 |
| Ellis, SP | 1 |
| Keilp, JG | 1 |
| Moitra, VK | 1 |
| Cooper, TB | 1 |
| Marver, JE | 1 |
| Burke, AK | 1 |
| Milak, MS | 1 |
| Sublette, ME | 1 |
| Oquendo, MA | 2 |
| Duncan, WC | 1 |
| Slonena, E | 1 |
| Hejazi, NS | 1 |
| Brutsche, N | 4 |
| Yu, KC | 1 |
| Park, L | 4 |
| Wills, K | 1 |
| Lally, N | 3 |
| Richards, EM | 9 |
| Luckenbaugh, DA | 22 |
| Walls, T | 1 |
| Ameli, R | 4 |
| Niciu, MJ | 14 |
| Brutsche, NE | 11 |
| van Wissen, K | 1 |
| Blanchard, D | 1 |
| Toprak, M | 1 |
| Turner, MS | 2 |
| Levine, SP | 1 |
| Katz, RB | 1 |
| Sanacora, G | 2 |
| Ajub, E | 1 |
| Camino, S | 1 |
| Tondo, L | 1 |
| Papolos, D | 1 |
| Frei, M | 1 |
| Rossignol, D | 1 |
| Mattis, S | 2 |
| Hernandez-Garcia, LC | 1 |
| Teicher, MH | 2 |
| Bigman, D | 1 |
| Kunaparaju, S | 1 |
| Bobrin, B | 1 |
| Zhang, M | 1 |
| Rosenheck, R | 1 |
| Li, Q | 1 |
| Xiao, Y | 1 |
| Huang, X | 1 |
| Fan, N | 1 |
| He, H | 1 |
| Wojdacz, R | 1 |
| Święcicki, Ł | 1 |
| Antosik-Wójcińska, A | 1 |
| Yarrington, JS | 2 |
| Farmer, CA | 2 |
| Lener, MS | 1 |
| Williams, D | 1 |
| Machado-Vieira, R | 12 |
| Shovestul, BJ | 1 |
| Jaso, BA | 1 |
| Farmer, C | 2 |
| Park, LT | 1 |
| Richards, E | 1 |
| Yuan, P | 4 |
| Li, HQ | 1 |
| Chen, LJ | 1 |
| Li, MD | 2 |
| Chan, LF | 1 |
| Eu, CL | 1 |
| Soh, SY | 1 |
| Maniam, T | 1 |
| Shahidii Kadir, Z | 1 |
| Chong, BTW | 1 |
| Loo, JL | 1 |
| Sharip, S | 1 |
| Wong, VCW | 1 |
| Loo, TH | 1 |
| Ng, YP | 1 |
| Kahn, DA | 1 |
| Guo, W | 1 |
| Mathew, S | 1 |
| Grunebaum, M | 1 |
| Akula, N | 1 |
| Henter, I | 1 |
| Merikangas, K | 1 |
| Drevets, W | 1 |
| Furey, M | 1 |
| McMahon, FJ | 1 |
| Shugart, YY | 1 |
| Wang, G | 1 |
| Krug, JT | 1 |
| Klein, AK | 1 |
| Purvis, EM | 1 |
| Ayala, K | 1 |
| Mayes, MS | 1 |
| Collins, L | 1 |
| Fisher, MPA | 1 |
| Ettenberg, A | 1 |
| Yu, L | 1 |
| Walter, M | 1 |
| Subramanieapillai, M | 1 |
| Banov, MD | 1 |
| Young, JR | 1 |
| Dunn, T | 1 |
| Szabo, ST | 1 |
| Post, RM | 1 |
| Nierenberg, AA | 2 |
| Howland, RH | 1 |
| Lara, DR | 1 |
| Munari, LR | 1 |
| Altinay, M | 1 |
| Anand, A | 2 |
| Ionescu, DF | 6 |
| Mathews, DC | 2 |
| Permoda-Osip, A | 4 |
| Dorszewska, J | 1 |
| Bartkowska-Sniatkowska, A | 4 |
| Chlopocka-Wozniak, M | 1 |
| Rybakowski, JK | 5 |
| Atigari, OV | 1 |
| Healy, D | 1 |
| Hjerrild, S | 1 |
| Bjerre, J | 1 |
| Pedersen, RH | 1 |
| Videbech, P | 1 |
| Nugent, AC | 3 |
| Diazgranados, N | 3 |
| Carlson, PJ | 1 |
| Ibrahim, L | 5 |
| Herscovitch, P | 1 |
| Drevets, WC | 1 |
| Kim, RD | 1 |
| Gazal, M | 3 |
| Valente, MR | 2 |
| Acosta, BA | 2 |
| Kaufmann, FN | 2 |
| Braganhol, E | 2 |
| Lencina, CL | 2 |
| Stefanello, FM | 2 |
| Ghisleni, G | 2 |
| Kaster, MP | 3 |
| Naughton, M | 1 |
| Clarke, G | 1 |
| O'Leary, OF | 1 |
| Cryan, JF | 1 |
| Dinan, TG | 1 |
| Nolan, NM | 2 |
| Guevara, S | 2 |
| Villaseñor, A | 1 |
| Ramamoorthy, A | 2 |
| Silva dos Santos, M | 1 |
| Lorenzo, MP | 1 |
| Laje, G | 2 |
| Zarate, C | 1 |
| Barbas, C | 1 |
| Wainer, IW | 3 |
| Lundin, NB | 2 |
| Kelly, TF | 1 |
| Lieberman, DZ | 1 |
| Fond, G | 2 |
| Loundou, A | 1 |
| Rabu, C | 1 |
| Macgregor, A | 1 |
| Lançon, C | 1 |
| Brittner, M | 1 |
| Micoulaud-Franchi, JA | 1 |
| Richieri, R | 1 |
| Courtet, P | 1 |
| Abbar, M | 1 |
| Roger, M | 1 |
| Leboyer, M | 1 |
| Boyer, L | 2 |
| Best, SR | 2 |
| McGirr, A | 1 |
| Berlim, MT | 1 |
| Roiser, JP | 1 |
| Kisielewski, J | 1 |
| Ortiz, R | 1 |
| Lukkahati, N | 1 |
| Saligan, LN | 2 |
| Liu, JX | 1 |
| Zerbo, E | 1 |
| Ross, S | 1 |
| Coyle, CM | 1 |
| Laws, KR | 1 |
| Griffin, BP | 1 |
| Pavel, DG | 1 |
| Oliveira, PS | 1 |
| Ortmann, CF | 1 |
| Sturbelle, R | 1 |
| Reginatto, FH | 2 |
| Dean, B | 1 |
| Gibbons, AS | 1 |
| Boer, S | 1 |
| Uezato, A | 1 |
| Meador-Woodruff, J | 1 |
| Scarr, E | 1 |
| McCullumsmith, RE | 1 |
| Ford, N | 1 |
| Ludbrook, G | 1 |
| Galletly, C | 1 |
| Kantrowitz, JT | 1 |
| Halberstam, B | 1 |
| Gangwisch, J | 1 |
| Xu, AJ | 1 |
| Walls, TL | 1 |
| Alison McInnes, L | 1 |
| James-Myers, MB | 1 |
| Soleimani, L | 1 |
| DeWilde, KE | 1 |
| Collins, KA | 1 |
| Lapidus, KA | 1 |
| Iacoviello, BM | 1 |
| Lener, M | 1 |
| Kautz, M | 1 |
| Kim, J | 1 |
| Stern, JB | 1 |
| Perez, AM | 1 |
| Brallier, JW | 1 |
| Rodriguez, GJ | 1 |
| Goodman, WK | 1 |
| Iosifescu, DV | 1 |
| Hasselmann, H | 1 |
| McCloud, TL | 1 |
| Caddy, C | 1 |
| Jochim, J | 1 |
| Rendell, JM | 1 |
| Diamond, PR | 1 |
| Shuttleworth, C | 1 |
| Brett, D | 1 |
| Amit, BH | 1 |
| Hamadi, L | 1 |
| Romeo, B | 1 |
| Choucha, W | 1 |
| Fossati, P | 1 |
| Rotge, JY | 1 |
| Parsaik, AK | 1 |
| Khosh-Chashm, D | 1 |
| Mascarenhas, SS | 1 |
| Slonena, EE | 1 |
| Marta, CJ | 1 |
| Yudofsky, LM | 1 |
| Enenbach, MJ | 1 |
| Kishimoto, T | 1 |
| Chawla, JM | 1 |
| Hagi, K | 1 |
| Kane, JM | 1 |
| Correll, CU | 1 |
| Sampath, H | 1 |
| Sharma, I | 1 |
| Dutta, S | 1 |
| Gold, PW | 2 |
| De Sousa, RT | 1 |
| Croarkin, PE | 1 |
| Leung, JG | 1 |
| Morgan, RJ | 1 |
| Rico, J | 1 |
| Palmer, BA | 1 |
| Ritter, MJ | 1 |
| Arslan, FC | 1 |
| Tiryaki, A | 1 |
| Yıldırım, M | 1 |
| Özkorumak, E | 1 |
| Alver, A | 1 |
| Altun, İK | 1 |
| İnce, İ | 1 |
| Gedikli, Ö | 1 |
| Beurel, E | 1 |
| Grieco, SF | 1 |
| Amadei, C | 1 |
| Downey, K | 1 |
| Jope, RS | 1 |
| Park, M | 1 |
| Newman, LE | 1 |
| Debom, G | 1 |
| Soares, MS | 1 |
| do Couto, CA | 1 |
| Mattos, B | 1 |
| Lencina, C | 1 |
| Ghisleni, GC | 1 |
| Tavares, R | 1 |
| Chaves, VC | 1 |
| Stefanello, F | 1 |
| Spanevello, RM | 1 |
| Pennybaker, SJ | 1 |
| Wendler, E | 1 |
| de Souza, CP | 1 |
| Vecchia, DD | 1 |
| Kanazawa, LKS | 1 |
| de Almeida Soares Hocayen, P | 1 |
| Wöhr, M | 1 |
| Schwarting, RKW | 1 |
| Andreatini, R | 1 |
| Rabl, U | 1 |
| Vanicek, T | 1 |
| Carlberg, L | 1 |
| Popovic, A | 1 |
| Spies, M | 1 |
| Bartova, L | 1 |
| Gryglewski, G | 1 |
| Papageorgiou, K | 1 |
| Lanzenberger, R | 1 |
| Willeit, M | 1 |
| Winkler, D | 1 |
| Kasper, S | 1 |
| Newberg, A | 1 |
| Kronstein, P | 1 |
| Khalife, S | 1 |
| Kammerer, WA | 1 |
| Quezado, Z | 1 |
| Salvadore, G | 1 |
| Manji, HK | 1 |
| Ricke, AK | 1 |
| Snook, RJ | 1 |
| Zhao, X | 1 |
| Venkata, SL | 2 |
| Moaddel, R | 2 |
| Mager, DE | 1 |
| Franco-Chaves, J | 2 |
| Cravchik, A | 1 |
| Selter, J | 1 |
| Marquardt, CA | 2 |
| Liberty, V | 1 |
| Coppola, M | 1 |
| Mondola, R | 1 |
| Fasula, M | 1 |
| Kelmendi, B | 1 |
| Ostroff, R | 1 |
| Cusin, C | 1 |
| Hilton, GQ | 1 |
| Loo, CK | 1 |
| Katalinic, N | 1 |
| Garfield, JB | 1 |
| Sainsbury, K | 1 |
| Hadzi-Pavlovic, D | 1 |
| Mac-Pherson, R | 1 |
| Mathews, D | 1 |
| Cassarly, C | 1 |
| Ghedim, FV | 1 |
| Fraga, Dde B | 1 |
| Deroza, PF | 1 |
| Oliveira, MB | 1 |
| Valvassori, SS | 1 |
| Steckert, AV | 1 |
| Budni, J | 1 |
| Dal-Pizzol, F | 1 |
| Quevedo, J | 1 |
| Zugno, AI | 1 |
| Skibinska, M | 1 |
| Adamski, R | 1 |
| Papolos, DF | 1 |
| Faedda, GL | 1 |
| Murphy, P | 1 |
| Dowben, JS | 1 |
| Grant, JS | 1 |
| Keltner, NL | 1 |
| Krystal, AD | 1 |
| Weiner, RD | 1 |
| Dean, MD | 1 |
| Lindahl, VH | 1 |
| Tramontozzi, LA | 1 |
| Falcone, G | 1 |
| Coffey, CE | 1 |
| Mason, OJ | 1 |
| Morgan, CJ | 1 |
| Stefanovic, A | 1 |
| Curran, HV | 1 |
| Laird, SM | 1 |
| Sage, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Investigation of the Rapid (Next Day) Antidepressant Effects of an NMDA Antagonist[NCT00088699] | Phase 1/Phase 2 | 67 participants (Actual) | Interventional | 2004-07-26 | Completed | ||
| A Double-blind Randomized Placebo-controlled Study of Aspirin and N-acetyl Cysteine as Adjunctive Treatments for Bipolar Disorder Patients (SMRI 11T-009)[NCT01797575] | Phase 2 | 38 participants (Actual) | Interventional | 2013-01-31 | Completed | ||
| Comparing Therapeutic Efficacy and Cognitive Side Effects of Electroconvulsive Therapy (ECT) Using Ketamine Versus Methohexital Anesthesia[NCT01881763] | Phase 4 | 31 participants (Actual) | Interventional | 2010-06-30 | Completed | ||
| Effect of Mini-dose Dexmedetomidine-Esketamine Infusion on Sleep Quality in Older Patients Undergoing Knee or Hip Replacement Surgery: A Multicenter Randomized Controlled Trial[NCT05950646] | Phase 4 | 154 participants (Anticipated) | Interventional | 2023-11-01 | Recruiting | ||
| A Randomized, Double-Blind, Support-of-Concept Phase 2 Study of Single-Dose Psilocybin for Major Depressive Disorder (MDD)[NCT03866174] | Phase 2 | 104 participants (Actual) | Interventional | 2019-10-15 | Completed | ||
| A Retrospective Chart Review of Patients Undergoing Ketamine Infusions at the Canadian Rapid Treatment Center of Excellence[NCT04209296] | 580 participants (Anticipated) | Observational | 2019-12-03 | Enrolling by invitation | |||
| A Single Ketamine Infusion Combined With Music for Suicidal Ideation During a Depressive Episode: A Randomized Open Label Clinical Trial[NCT04658420] | Phase 2 | 200 participants (Anticipated) | Interventional | 2021-07-01 | Not yet recruiting | ||
| Ketamine for Severe Adolescent Depression: Intermediate-term Safety and Efficacy[NCT03889756] | Phase 2/Phase 3 | 3 participants (Actual) | Interventional | 2019-07-17 | Terminated (stopped due to No more funding available to continue since we could not recruit throughout the pandemic.) | ||
| Open Study of the Neurobiological Effects of Intranasal Ketamine in Children and Adults With Bipolar Disorder - Fear of Harm Phenotype[NCT05209217] | 20 participants (Anticipated) | Observational | 2019-06-04 | Recruiting | |||
| Music as a Potential Intervention to Improve Hemodynamic Tolerability of Repetitive Sub-Anesthetic IV Ketamine Infusions in Bipolar and Unipolar Depression: A Pilot Study[NCT04701866] | 32 participants (Actual) | Interventional | 2021-01-11 | Completed | |||
| Radical aiTBS Protocol for Intractable Depression[NCT04441008] | 50 participants (Anticipated) | Interventional | 2023-12-31 | Not yet recruiting | |||
| A Pilot Study of the Use of Oral Ketamine for Treatment of Vaso-Occlusive Pain in Adolescents and Young Adults[NCT05378555] | Phase 3 | 10 participants (Anticipated) | Interventional | 2023-05-01 | Recruiting | ||
| Effect of S-ketamine on Depressed Patients Undergoing Electroconvulsive Therapy-a Randomized, Double-blind, Controlled Clinical Study[NCT04399070] | 150 participants (Anticipated) | Interventional | 2020-08-01 | Not yet recruiting | |||
| Conscious Dying/Conscious Living: Ketamine-Assisted Psychotherapy (KAP) for Patients at End of Life-A Pilot Study for Palliative and Hospice Care[NCT05214417] | Phase 2 | 120 participants (Anticipated) | Interventional | 2022-05-01 | Not yet recruiting | ||
| Evaluation of Schemes of Administration of Intravenous Ketamine in Treatment-resistant Depression: Clinical-neuroimaging Correlation[NCT03742557] | Phase 3 | 30 participants (Anticipated) | Interventional | 2018-10-01 | Recruiting | ||
| Intramuscular Ketamine Versus Escitalopram and Aripiprazole in Acute and Maintenance Treatment of Patients With Treatment-resistant Depression[NCT04234776] | Phase 4 | 88 participants (Anticipated) | Interventional | 2018-04-03 | Enrolling by invitation | ||
| Effects of Low Dose Ketamine Given at Induction of Anesthesia on Postoperative Mood in Patients With Depressive Symptoms[NCT02422303] | 12 participants (Actual) | Interventional | 2015-12-31 | Terminated | |||
| A Safe Ketamine-Based Therapy for Treatment Resistant Depression[NCT01179009] | 20 participants (Actual) | Interventional | 2012-04-30 | Completed | |||
| A Pilot Study of a Single Infusion of Ketamine in Relief of Depressive Symptoms of Elderly Patients With Visual Impairment.[NCT03473431] | 90 participants (Actual) | Interventional | 2018-04-15 | Completed | |||
| Ketamine Co-induction for Patients With Major Depressive Disorder; a Randomized Clinical Trial[NCT03666494] | Phase 4 | 50 participants (Anticipated) | Interventional | 2018-12-31 | Not yet recruiting | ||
| Effects of Low-dose S-ketamine on the Incidence of Postpartum Depression in Women With Prenatal Depression: a Randomized, Double-blind, Placebo-controlled Trial[NCT04414943] | 364 participants (Actual) | Interventional | 2020-06-19 | Completed | |||
| Effects of Low-dose S-Ketamine on Incidence of Postpartum Depression in Parturients With Prenatal Depression: A Randomized, Double-blind, Placebo-controlled Trial[NCT03927378] | 364 participants (Actual) | Interventional | 2020-06-19 | Completed | |||
| Anhedonia, Development, and Emotions: Phenotyping and Therapeutics (ADEPT) Study[NCT05487885] | Phase 4 | 275 participants (Anticipated) | Interventional | 2022-07-22 | Recruiting | ||
| Ketamine's Actions on Rumination Mechanisms as an Antidepressant[NCT04656886] | 37 participants (Actual) | Interventional | 2014-09-30 | Completed | |||
| ED Treatment of Suicidal Patients With Ketamine Infusion[NCT03502551] | Phase 2 | 0 participants (Actual) | Interventional | 2019-04-01 | Withdrawn (stopped due to Trial never received funding.) | ||
| Investigating Rapid Anti-Suicidal Ideation Effects of Intravenous (IV) Ketamine in Hospitalized Patients[NCT01507181] | Phase 4 | 24 participants (Actual) | Interventional | 2012-01-31 | Completed | ||
| The Effect of Therapeutic Ketamine Infusions on the Symptoms of Post-Traumatic Stress Disorder in Combat Veterans[NCT03088384] | 30 participants (Actual) | Observational | 2016-11-28 | Completed | |||
| Evaluation of the Antidepressant Effects of Nitrous Oxide in People With Major Depressive Disorder[NCT05357040] | Phase 2 | 172 participants (Anticipated) | Interventional | 2021-06-30 | Recruiting | ||
| A Proof-of-Concept Trial on the Effect of Ketamine on Fatigue[NCT04141696] | Phase 1/Phase 2 | 59 participants (Anticipated) | Interventional | 2021-07-26 | Recruiting | ||
| Effects of Low-dose Dexmedetomidine-esketamine Combined Nasal Administration at Night on Perioperative Sleep Quality in Breast Cancer Patients: a Randomized, Double-blind, Placebo-controlled Trial[NCT05732064] | Phase 4 | 180 participants (Anticipated) | Interventional | 2023-05-22 | Recruiting | ||
| Acute and Maintenance Intravenous Ketamine for Treatment Resistant Major Depression With Suicidal Ideation/Attempt[NCT02094898] | Phase 2 | 12 participants (Actual) | Interventional | 2014-09-30 | Completed | ||
| A Prospective Randomized Double Blinded Control Trial Using Ketamine or Propofol Anesthesia for Electroconvulsive Therapy: Improving Treatment-Resistant Depression[NCT01935115] | Phase 4 | 27 participants (Actual) | Interventional | 2013-09-30 | Completed | ||
| Clinical Trial of the Use of Ketamine in Treatment Resistant Depression[NCT02610712] | Phase 4 | 20 participants (Anticipated) | Interventional | 2014-05-31 | Recruiting | ||
| A Study of Ketamine as an Antidepressant[NCT01441505] | Phase 2 | 42 participants (Anticipated) | Interventional | 2011-09-30 | Recruiting | ||
| Initiating Ketamine in Acutely Suicidal Patients in the Emergency Department[NCT04260607] | Phase 3 | 2 participants (Actual) | Interventional | 2020-01-14 | Terminated (stopped due to As a busy MTF we were unable to retain a health care provider with the appropriate expertise to buy-in to this study once the initiating PI left military service.) | ||
| Evaluation of the Initial Prescription of Ketamine and Milnacipran Forin Depression in Patients With a Progressive Disease[NCT02783430] | Phase 2/Phase 3 | 80 participants (Anticipated) | Interventional | 2016-09-08 | Recruiting | ||
| A Double-blind Randomised, Placebo-controlled Study of Adjunctive Ketamine Anaesthesia in ECT (Electroconvulsive Therapy)[NCT00680433] | Phase 4 | 83 participants (Actual) | Interventional | 2008-04-30 | Completed | ||
| Ketamine Treatment for Pediatric-Refractory Obsessive-Compulsive Disorder (OCD)[NCT02422290] | Phase 1/Phase 2 | 5 participants (Actual) | Interventional | 2015-03-31 | Completed | ||
| Effect of Subanesthetic Dose of Ketamine Combined With Propofol on Cognitive Function in Depressive Patients Undergoing Electroconvulsive Therapy ---a Randomized Control Double-Blind Clinical Trial[NCT02305394] | Phase 4 | 132 participants (Anticipated) | Interventional | 2015-01-31 | Not yet recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Antidepressant effects were assessed using the Montgomery-Åsberg Depression Rating Scale (MADRS). It is a ten-item diagnostic questionnaire which psychiatrists use to measure the severity of depressive episodes. Higher MADRS score indicates more severe depression, and each item yields a score of 0 to 6. The overall score ranges from 0 to 60. (NCT00088699)
Timeframe: Baseline
| Intervention | units on a scale (Mean) |
|---|---|
| Ketamine - Healthy Volunteers | 1.17 |
| Placebo - Healthy Volunteers | 1.48 |
| Ketamine - MDD Patients | 33.83 |
| Placebo - MDD Patients | 31.82 |
Antidepressant effects were assessed using the Montgomery-Åsberg Depression Rating Scale (MADRS). It is a ten-item diagnostic questionnaire which psychiatrists use to measure the severity of depressive episodes. Higher MADRS score indicates more severe depression, and each item yields a score of 0 to 6. The overall score ranges from 0 to 60. (NCT00088699)
Timeframe: Day 1
| Intervention | units on a scale (Mean) |
|---|---|
| Ketamine - Healthy Volunteers | 2.45 |
| Placebo - Healthy Volunteers | 0.67 |
| Ketamine - MDD Patients | 23.73 |
| Placebo - MDD Patients | 30.68 |
The MADRS is a ten-item diagnostic questionnaire used to measure the severity of depressive episodes in patients with mood disorders. A higher MADRS score indicates more severe depression, and each item yields a score of 0 to 6. The overall score ranges from 0 to 60. The questionnaire includes questions on the following symptoms: 1. Apparent sadness; 2. Reported sadness; 3. Inner tension; 4. Reduced sleep; 5. Reduced appetite; 6. Concentration difficulties; 7. Lassitude; 8. Inability to feel; 9. Pessimistic thoughts; and 10. Suicidal thoughts. This 30% MADRS reduction was analyzed in addition to initial outcome measures of 50% MADRS reduction due to the smaller than expected study sample size. (NCT01797575)
Timeframe: Received drug for 8 weeks during week 0 to week 8 of the study
| Intervention | Participants (Count of Participants) |
|---|---|
| Aspirin and NAC | 3 |
| Aspirin | 2 |
| N-Acetyl Cysteine (NAC) | 6 |
| Placebo | 7 |
The MADRS is a ten-item diagnostic questionnaire used to measure the severity of depressive episodes in patients with mood disorders. A higher MADRS score indicates more severe depression, and each item yields a score of 0 to 6. The overall score ranges from 0 to 60. The questionnaire includes questions on the following symptoms: 1. Apparent sadness; 2. Reported sadness; 3. Inner tension; 4. Reduced sleep; 5. Reduced appetite; 6. Concentration difficulties; 7. Lassitude; 8. Inability to feel; 9. Pessimistic thoughts; and 10. Suicidal thoughts. This 30% MADRS reduction was analyzed in addition to initial outcome measures of 50% MADRS reduction due to the smaller than expected study sample size. (NCT01797575)
Timeframe: Received drug for 8 weeks during week 9 to week 16 of the study
| Intervention | Participants (Count of Participants) |
|---|---|
| Aspirin and NAC | 4 |
| Aspirin | 3 |
| N-Acetyl Cysteine (NAC) | 3 |
| Placebo | 4 |
The MADRS is a ten-item diagnostic questionnaire used to measure the severity of depressive episodes in patients with mood disorders. A higher MADRS score indicates more severe depression, and each item yields a score of 0 to 6. The overall score ranges from 0 to 60. The questionnaire includes questions on the following symptoms: 1. Apparent sadness; 2. Reported sadness; 3. Inner tension; 4. Reduced sleep; 5. Reduced appetite; 6. Concentration difficulties; 7. Lassitude; 8. Inability to feel; 9. Pessimistic thoughts; and 10. Suicidal thoughts. (NCT01797575)
Timeframe: Received drug for 8 weeks during week 0 to week 8 of the study
| Intervention | Participants (Count of Participants) |
|---|---|
| Aspirin and NAC | 3 |
| Aspirin | 2 |
| N-Acetyl Cysteine (NAC) | 5 |
| Placebo | 6 |
The MADRS is a ten-item diagnostic questionnaire used to measure the severity of depressive episodes in patients with mood disorders. A higher MADRS score indicates more severe depression, and each item yields a score of 0 to 6. The overall score ranges from 0 to 60. The questionnaire includes questions on the following symptoms: 1. Apparent sadness; 2. Reported sadness; 3. Inner tension; 4. Reduced sleep; 5. Reduced appetite; 6. Concentration difficulties; 7. Lassitude; 8. Inability to feel; 9. Pessimistic thoughts; and 10. Suicidal thoughts. (NCT01797575)
Timeframe: Received drug for 8 weeks during week 9 to week 16 of the study
| Intervention | Participants (Count of Participants) |
|---|---|
| Aspirin and NAC | 3 |
| Aspirin | 1 |
| N-Acetyl Cysteine (NAC) | 3 |
| Placebo | 4 |
C-reactive protein (CRP) levels are blood test markers of inflammation. Higher CRP corresponds with higher levels of inflammation. CRP is measured in milligrams per liter. (NCT01797575)
Timeframe: baseline, week 8, week 16
| Intervention | milligrams per liter (Mean) | ||
|---|---|---|---|
| CRP at Baseline | CRP at Week 8 | CRP at Week 16 | |
| Aspirin | 6.85 | 6.82 | 10.76 |
| Aspirin and NAC | 5.1 | 17.02 | 9.39 |
| N-acetyl-cysteine | 17.65 | 41.09 | 17.69 |
| Sugar Pill | 17.30 | 7.4 | 13.10 |
Interleukin 6 (IL-6) is an interleukin that acts as a pro-inflammatory cytokine and an anti-inflammatory myokine. IL-6 is measured in picograms (pg) per milliliter (mL). Elevated interleukin-6 indicates potential immune system dysregulation and increased inflammation. (NCT01797575)
Timeframe: baseline, week 8, week 16
| Intervention | picograms per milliliter (Mean) | ||
|---|---|---|---|
| IL-6 at Baseline | IL-6 at Week 8 | IL-6 at Week 16 | |
| Aspirin | 1.27 | .78 | .90 |
| Aspirin and NAC | .85 | 1.76 | 1.72 |
| N-acetyl-cysteine | 3.22 | 3.53 | 2.6 |
| Sugar Pill | 2.3 | 1.87 | 1.71 |
The items mostly range from a score of 0-4 but there are some questions that range from a score of 0-2. The maximum total score that can be reported is 76 and the lowest score is 0. Higher values represent a worse outcome. Items are summed together to compute the total score. Remission is defined as two consecutive Hamilton Rating Scale for Depression, 24 items (HRSD-24) scores < 10, and HRSD-24 total score does not increase > 3 points on the second consecutive HRSD-24, or remains < 6 at the last two consecutive treatments. HRSD-24 scores are used to define remission. (NCT01881763)
Timeframe: Days required to achieve remission (on average 3-4 weeks)
| Intervention | HRSD units (Mean) |
|---|---|
| Ketamine | 7.82 |
| Methohexital | 8.60 |
Establish if repeated ketamine will be efficacious medically and psychiatrically, as measured by a significant reduction in CDRS score in those treated with ketamine at the end of the dosing paradigm. The Children's Depression Rating Scale (CDRS) is a clinician-rated instrument with 17 items scored on a 1 to 5 or 1 to 7 scale. A rating of 1 indicates normal, thus the minimum score is 17. The maximum score is 113. Scores of 20-30 suggest borderline depression. Scores of 40-60 indicate moderate depression. (NCT03889756)
Timeframe: Day 18
| Intervention | score on a scale (Mean) |
|---|---|
| Ketamine | 42 |
| Midazolam | 62 |
Establish if repeated ketamine will be tolerated as measured by drop-out counts. (NCT03889756)
Timeframe: Day 18
| Intervention | Participants (Count of Participants) |
|---|---|
| Ketamine | 0 |
| Midazolam | 0 |
The Montgomery-Asberg Depression Rating Scale (MADRS) is a 10-item scale that measures the severity of depression, with a higher score indicating a higher level of depression. The range of scores is 0 to 60. (NCT01179009)
Timeframe: 8 weeks
| Intervention | Scores on a scale (Mean) |
|---|---|
| Ketamine 100-hour Infusion | -9.0 |
| Ketamine 40-minute Infusion | -6.4 |
Change in BSI score at 24 hours following treatment as compared to baseline. Beck Scale is a 21-item self or clinician administered instrumentation used to measure the current intensity of patients' specific attitudes, behaviors and plans to commit suicide. Score range 0-42, with higher score indicating higher intensity. (NCT01507181)
Timeframe: baseline and 24 hours post infusion
| Intervention | units on a scale (Mean) |
|---|---|
| Ketamine | 10.8 |
| Midazolam | 14.0 |
Change in BSI score at 48 hours following treatment as compared to baseline. Beck Scale is a 21-item self or clinician administered instrumentation used to measure the current intensity of patients' specific attitudes, behaviors and plans to commit suicide. Score range 0-42, with higher score indicating higher intensity. (NCT01507181)
Timeframe: baseline and 48 hours post infusion
| Intervention | units on a scale (Mean) |
|---|---|
| Ketamine | 8.8 |
| Midazolam | 15.3 |
The PRISE assesses the presence of treatment side effects in nine organ/function systems (gastrointestinal, nervous system, heart, eyes/ears, skin, genital/urinary, sleep, sexual functioning, and other). Data reported in in Adverse Events section. (NCT01507181)
Timeframe: duration of study
| Intervention | events (Number) |
|---|---|
| Ketamine | 29 |
| Midazolam | 23 |
The MADRS-SI ranges from 0 to 6; a score of 2 corresponds to fleeting, passive SI; a score of 4 indicates that SI is frequent with at least moderate intensity but without specific plans or intention; a score of 6 corresponds to active intention and planning for suicide. (NCT01507181)
Timeframe: 24 hours post infusion
| Intervention | units on a scale (Mean) |
|---|---|
| Ketamine | 1.8 |
| Midazolam | 3.3 |
The MADRS is a 10-item instrument used for the evaluation of depressive symptoms in adults and for the assessment of any changes to those symptoms. Higher MADRS score indicates more severe depression, and each item yields a score of 0 to 6. The overall score ranges from 0 to 60. (NCT01507181)
Timeframe: up to 7 days post infusion
| Intervention | units on a scale (Mean) | |||
|---|---|---|---|---|
| 24 hours | 48 hours | 72 hours | 7 days | |
| Ketamine | 19.0 | 19.3 | 20.9 | 21.7 |
| Midazolam | 26.2 | 28 | 24.1 | 22.2 |
The BPRS measures psychomimetic effects with higher scores indicating more severe symptoms (scale range 7 - 49). (NCT01507181)
Timeframe: baseline, 40 minutes post infusion, and 240 minutes post infusion
| Intervention | units on a scale (Mean) | ||
|---|---|---|---|
| baseline | 40 minutes post infusion | 240 minutes post infusion | |
| Ketamine | 7.7 | 9.9 | 8.1 |
| Midazolam | 7.7 | 7.9 | 7.0 |
The CADSS measures dissociation with higher scores indicating more severe symptoms (scale range 0 - 92). (NCT01507181)
Timeframe: baseline, 40 minutes post infusion and 240 minutes post infusion
| Intervention | units on a scale (Mean) | ||
|---|---|---|---|
| baseline | 40 minutes post infusion | 240 minutes post infusion | |
| Ketamine | 1.1 | 17.1 | 1.2 |
| Midazolam | 4.0 | 3.3 | 1.3 |
An 11-item questionnaire, used to assess manic symptoms based on the patient's subjective report of his or her clinical condition. There are four items that are graded on a 0 to 8 scale (irritability, speech, thought content, and disruptive/aggressive behavior), while the remaining seven items are graded on a 0 to 4 scale. The scores from each question are added together to form a total score ranging from 0 to 60, with higher scores indicating a greater severity of symptoms. (NCT01507181)
Timeframe: baseline, 40 minutes post infusion, 240 minutes post infusion
| Intervention | units on a scale (Mean) | ||
|---|---|---|---|
| baseline | 40 minutes post infusion | 240 minutes post infusion | |
| Ketamine | 0.0 | 0.0 | 0.2 |
| Midazolam | 0.1 | 0.3 | 0.2 |
The Clinical Global Impression Severity Subscale is an observer rated scale that measures illness severity. It has a range of responses from 1 (normal) through to 7 (among the most extremely ill patients). (NCT02094898)
Timeframe: baseline, last acute phase observation (approximately 2 weeks)
| Intervention | percentage change in score (Mean) |
|---|---|
| Entire Cohort | -29.4 |
| Remission | -50.7 |
| Non-Remission | -14.3 |
The MADRS test includes 10 items and uses a 0 to 6 severity scale for each item, with higher scores indicating increasing depressive symptoms. MADRS Factor 1 (Sadness) consisted of MADRS items 1 (Apparent Sadness) and 2 (Reported Sadness). The MADRS Factor 1 Score is derived by adding all the scores from the 2 items, meaning the lowest possible score is 0 and the highest possible is 12. (NCT02094898)
Timeframe: baseline, last acute phase observation
| Intervention | percentage change in score (Mean) |
|---|---|
| Entire Cohort | -50.3 |
| Remission | -83.6 |
| Non-Remission | -26.5 |
The MADRS test includes 10 items and uses a 0 to 6 severity scale for each item, with higher scores indicating increasing depressive symptoms. MADRS Factor 2 (negative thoughts) consisted of MADRS items 9 (Pessimistic Thoughts) and 10 (Suicidal Thoughts). The MADRS Factor 2 Score is derived by adding all the scores from the 2 items, meaning the lowest possible score is 0 and the highest possible is 12. (NCT02094898)
Timeframe: baseline, last acute phase observation (approximately 2 weeks)
| Intervention | percentage change in score (Mean) |
|---|---|
| Entire Cohort | -37.0 |
| Remission | -65.4 |
| Non-Remission | -16.7 |
The MADRS test includes 10 items and uses a 0 to 6 severity scale for each item, with higher scores indicating increasing depressive symptoms. MADRS Factor 3 (detachment) consisted of MADRS items 6 - 8 (Concentration Difficulties, Lassitude, and Inability to Feel). The MADRS Factor 3 Score is derived by adding all the scores from the 3 items, meaning the lowest possible score is 0 and the highest possible is 18. (NCT02094898)
Timeframe: baseline, last acute phase observation (approximately 2 weeks)
| Intervention | percentage change in score (Mean) |
|---|---|
| Entire Cohort | -40.2 |
| Remission | -84.3 |
| Non-Remission | -8.9 |
The MADRS test includes 10 items and uses a 0 to 6 severity scale for each item, with higher scores indicating increasing depressive symptoms. MADRS Factor 4 (neurovegetative symptoms) consisted of MADRS items 3-5 (Inner Tension, Reduced Sleep, and Reduced Appetite). The MADRS Factor 4 Score is derived by adding all the scores from the 3 items, meaning the lowest possible score is 0 and the highest possible is 18. (NCT02094898)
Timeframe: baseline, last acute phase observation (approximately 2 weeks)
| Intervention | percentage change in score (Mean) |
|---|---|
| Entire Cohort | -36.0 |
| Remission | -84.3 |
| Non-Remission | -8.4 |
The MADRS test includes 10 items and uses a 0 to 6 severity scale for each item, with higher scores indicating increasing depressive symptoms. Item 10 scores can range from 0 to 6 (with 0 indicating enjoying life, and 6 indicating explicit plans for suicide.) (NCT02094898)
Timeframe: baseline, last acute phase observation (approximately 2 weeks)
| Intervention | percentage change in score (Mean) |
|---|---|
| Entire Cohort | -26.7 |
| Remission | -50.0 |
| Non-Remission | -7.2 |
The Montgomery Asberg Depression Scale (MADRS) is a 10-item observer rating scale assessing symptoms of depression. The score ranges from 0 (no depression) to 60 (very depressed). For this study a score of less than or equal to 9 was considered clinical remission of depression. (NCT02094898)
Timeframe: baseline, last acute phase observation (approximately 2 weeks)
| Intervention | percentage change in score (Mean) |
|---|---|
| Entire Cohort | -41.5 |
| Remission | -79.1 |
| Non-Remission | -14.5 |
The Clinical Global Impression Severity Subscale is an observer rated scale that measures illness severity. It has a range of responses from 1 (normal) through to 7 (among the most extremely ill patients). (NCT02094898)
Timeframe: baseline, last acute phase observation (approximately 2 weeks)
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Baseline | Last acute phase observation | |
| Entire Cohort | 5.6 | 3.9 |
| Non-Remission | 5.7 | 4.9 |
| Remission | 5.4 | 2.6 |
The MADRS test includes 10 items and uses a 0 to 6 severity scale for each item, with higher scores indicating increasing depressive symptoms. MADRS Factor 1 (Sadness) consisted of MADRS items 1 (Apparent Sadness) and 2 (Reported Sadness). The MADRS Factor 1 Score is derived by adding all the scores from the 2 items, meaning the lowest possible score is 0 and the highest possible is 12. (NCT02094898)
Timeframe: baseline, last acute phase observation (approximately 2 weeks)
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Baseline | Last acute phase observation | |
| Entire Cohort | 7.4 | 3.5 |
| Non-Remission | 7.4 | 5.1 |
| Remission | 7.4 | 1.2 |
The MADRS test includes 10 items and uses a 0 to 6 severity scale for each item, with higher scores indicating increasing depressive symptoms. MADRS Factor 2 (Negative Thoughts) consisted of MADRS items 9 (Pessimistic Thoughts) and 10 (Suicidal Thoughts). The MADRS Factor 2 Score is derived by adding all the scores from the 2 items, meaning the lowest possible score is 0 and the highest possible is 12. (NCT02094898)
Timeframe: baseline, last acute phase observation (approximately 2 weeks)
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Baseline | Last acute phase observation | |
| Entire Cohort | 6.0 | 3.4 |
| Non-Remission | 5.9 | 4.6 |
| Remission | 6.2 | 1.8 |
The MADRS test includes 10 items and uses a 0 to 6 severity scale for each item, with higher scores indicating increasing depressive symptoms. MADRS Factor 3 (Detachment) consisted of MADRS items 6 - 8 (Concentration Difficulties, Lassitude, and Inability to Feel). The MADRS Factor 3 Score is derived by adding all the scores from the 3 items, meaning the lowest possible score is 0 and the highest possible is 18. (NCT02094898)
Timeframe: baseline, last acute phase observation (approximately 2 weeks)
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Baseline | Last acute phase observation | |
| Entire Cohort | 9.5 | 4.9 |
| Non-Remission | 9.3 | 7.4 |
| Remission | 9.8 | 1.4 |
The MADRS test includes 10 items and uses a 0 to 6 severity scale for each item, with higher scores indicating increasing depressive symptoms. MADRS Factor 4 (Neurovegetative Symptoms) consisted of MADRS items 3-5 (Inner Tension, Reduced Sleep, and Reduced Appetite). The MADRS Factor 4 Score is derived by adding all the scores from the 3 items, meaning the lowest possible score is 0 and the highest possible is 18. (NCT02094898)
Timeframe: baseline, last acute phase observation (approximately 2 weeks)
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Baseline | Last acute phase observation | |
| Entire Cohort | 6.5 | 3.8 |
| Non-Remission | 6.9 | 5.9 |
| Remission | 6.0 | 1.0 |
The MADRS test includes 10 items and uses a 0 to 6 severity scale for each item, with higher scores indicating increasing depressive symptoms. Item 10 scores can range from 0 to 6 (with 0 indicating enjoying life, and 6 indicating explicit plans for suicide.) (NCT02094898)
Timeframe: baseline, last acute phase observation (approximately 2 weeks)
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Baseline | Last acute phase observation | |
| Entire Cohort | 2.9 | 1.7 |
| Non-Remission | 2.7 | 2.2 |
| Remission | 3.2 | 1.2 |
The Montgomery Asberg Depression Scale (MADRS) is a 10-item observer rating scale assessing symptoms of depression. The score ranges from 0 (no depression) to 60 (very depressed). For this study a score of less than or equal to 9 was considered clinical remission of depression. (NCT02094898)
Timeframe: baseline, last acute phase observation (approximately 2 weeks)
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Baseline | Last acute phase observation | |
| Entire Cohort | 29.4 | 15.9 |
| Non-Remission | 29.4 | 23.4 |
| Remission | 29.4 | 5.4 |
The CY-BOCS is a semi-structured measure of OCD severity with excellent inter-rater reliability, internal consistency, and test-retest reliability. It is validated in those starting at age 7 and used in studies up to age 20. The CYBOCS differs from the adult YBOCS only in its use of simpler language. The CY-BOCS consists of 10 items which are summed up to derive the total CY-BOCS score. The total score ranges from 0-40 with higher scores indicating greater severity of OCD symptoms. (NCT02422290)
Timeframe: Screening, Baseline, Day 7, Day 17, 3-Month; Baseline and Day 14 pre-specified to be reported
| Intervention | score on a scale (Mean) | |
|---|---|---|
| CY-BOCS Baseline | CY-BOCS Day 14 | |
| Ketamine Treatment Group | 29.00 | 26.20 |
The CGI-S is a clinician rated 7-point rating scale for the severity of a participant's illness relative to the clinician's experience of working with this particular population. The score ranges from 1-7 with higher scores indicating greater illness severity. (NCT02422290)
Timeframe: Screening, Baseline, Day 7, Day 17, 3-Month; Baseline and Day 14 pre-specified to be reported
| Intervention | score on a scale (Mean) | |
|---|---|---|
| CGI-S Baseline | CGI-S Day 14 | |
| Ketamine Treatment Group | 5.80 | 5.00 |
"The OCD-VAS is a one-item unipolar scale to assess OCD symptoms over a rapid time frame (No obsessions to Constant obsessions). The scale ranges from 0-10 with higher scores indicating higher presence of obsessions." (NCT02422290)
Timeframe: Screening, Baseline, Day 1-14, 3-Month; Baseline and Day 14 pre-specified to be reported
| Intervention | score on a scale (Mean) | |
|---|---|---|
| OCD-VAS Baseline | OCD-VAS Day 14 | |
| Ketamine Treatment Group | 5.00 | 5.00 |
"The Y-BOCCS is self-report scale which assesses OCD symptoms on a 5-point likert scale (None to Extreme). It consists of 10 items which are summed up to derive the total Y-BOCCS score. The total score ranges from 0-40 with higher scores indicating higher prevalence of OCD symptoms." (NCT02422290)
Timeframe: Screening, Baseline, Day 1-14, 3-Month; Baseline and Day 14 pre-specified to be reported
| Intervention | score on a scale (Mean) | |
|---|---|---|
| Y-BOCCS Baseline | Y-BOCCS Day 14 | |
| Ketamine Treatment Group | 18.25 | 16.50 |
44 reviews available for ketamine and Affective Psychosis, Bipolar
| Article | Year |
|---|---|
Ketamine and other glutamate receptor modulators for depression in adults with bipolar disorder.
Topics: Adult; Bipolar Disorder; Depression; Humans; Ketamine; Quality of Life; Receptors, Glutamate | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with bipolar disorder.
Topics: Adult; Bipolar Disorder; Depression; Humans; Ketamine; Quality of Life; Receptors, Glutamate | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with bipolar disorder.
Topics: Adult; Bipolar Disorder; Depression; Humans; Ketamine; Quality of Life; Receptors, Glutamate | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with bipolar disorder.
Topics: Adult; Bipolar Disorder; Depression; Humans; Ketamine; Quality of Life; Receptors, Glutamate | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with bipolar disorder.
Topics: Adult; Bipolar Disorder; Depression; Humans; Ketamine; Quality of Life; Receptors, Glutamate | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with bipolar disorder.
Topics: Adult; Bipolar Disorder; Depression; Humans; Ketamine; Quality of Life; Receptors, Glutamate | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with bipolar disorder.
Topics: Adult; Bipolar Disorder; Depression; Humans; Ketamine; Quality of Life; Receptors, Glutamate | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with bipolar disorder.
Topics: Adult; Bipolar Disorder; Depression; Humans; Ketamine; Quality of Life; Receptors, Glutamate | 2021 |
Ketamine and other glutamate receptor modulators for depression in adults with bipolar disorder.
Topics: Adult; Bipolar Disorder; Depression; Humans; Ketamine; Quality of Life; Receptors, Glutamate | 2021 |
Ketamine for psychotic depression: An overview of the glutamatergic system and ketamine's mechanisms associated with antidepressant and psychotomimetic effects.
Topics: Antidepressive Agents; Bipolar Disorder; Depression; Depressive Disorder, Major; Humans; Ketamine | 2021 |
The Effects of Ketamine on Cognition in Unipolar and Bipolar Depression: A Systematic Review.
Topics: Administration, Intravenous; Adolescent; Adult; Aged; Bipolar Disorder; Cognition; Depressive Disord | 2022 |
[The role of ketamine in the treatment of treatment-resistant bipolar depression].
Topics: Antidepressive Agents; Bipolar Disorder; Depression; Depressive Disorder, Treatment-Resistant; Drug- | 2021 |
Rapid cycling bipolar disorder: Literature review on pharmacological treatment illustrated by a case report on ketamine.
Topics: Anticonvulsants; Antidepressive Agents; Antimanic Agents; Antipsychotic Agents; Bipolar Disorder; Hu | 2022 |
[Practical aspects of ketamine treatment-Safety, combination treatment and comorbidities].
Topics: Antidepressive Agents; Bipolar Disorder; Depressive Disorder, Major; Humans; Ketamine; Suicidal Idea | 2022 |
A Systematic Review of Neurocognitive Effects of Subanesthetic Doses of Intravenous Ketamine in Major Depressive Disorder, Post-Traumatic Stress Disorder, and Healthy Population.
Topics: Adult; Antidepressive Agents; Bipolar Disorder; Depressive Disorder, Major; Humans; Ketamine; Recept | 2022 |
International pooled patient-level meta-analysis of ketamine infusion for depression: In search of clinical moderators.
Topics: Administration, Intravenous; Antidepressive Agents; Bipolar Disorder; Depression; Humans; Ketamine; | 2022 |
Rethinking ketamine and esketamine action: Are they antidepressants with mood-stabilizing properties?
Topics: Antidepressive Agents; Bipolar Disorder; Depression; Depressive Disorder, Major; Depressive Disorder | 2023 |
New Pharmacologic Approaches to the Treatment of Bipolar Depression.
Topics: Antidepressive Agents; Bipolar Disorder; Depression; Humans; Ketamine; Psilocybin; Randomized Contro | 2023 |
Ketamine in neuropsychiatric disorders: an update.
Topics: Anhedonia; Antidepressive Agents; Anxiety Disorders; Bipolar Disorder; Depression; Humans; Ketamine | 2024 |
Efficacy of Ketamine in bipolar depression: focus on anhedonia.
Topics: Anhedonia; Antidepressive Agents; Bipolar Disorder; Depression; Humans; Ketamine | 2019 |
Safety and Tolerability of Ketamine Use in Treatment-Resistant Bipolar Depression Patients with Regard to Central Nervous System Symptomatology: Literature Review and Analysis.
Topics: Administration, Intravenous; Administration, Oral; Antidepressive Agents; Bipolar Disorder; Comorbid | 2020 |
The relationship between subjective effects induced by a single dose of ketamine and treatment response in patients with major depressive disorder: A systematic review.
Topics: Antidepressive Agents; Bipolar Disorder; Depressive Disorder, Major; Dissociative Disorders; Humans; | 2020 |
Efficacy of single and repeated administration of ketamine in unipolar and bipolar depression: a meta-analysis of randomized clinical trials.
Topics: Antidepressive Agents; Bipolar Disorder; Depressive Disorder, Major; Ketamine; Randomized Controlled | 2020 |
A systematic review of therapeutic ketamine use in children and adolescents with treatment-resistant mood disorders.
Topics: Adolescent; Adult; Antidepressive Agents; Bipolar Disorder; Child; Depressive Disorder, Treatment-Re | 2021 |
Targeting Homeostatic Synaptic Plasticity for Treatment of Mood Disorders.
Topics: Animals; Antimanic Agents; Bipolar Disorder; Depressive Disorder, Major; Depressive Disorder, Treatm | 2020 |
The concept and management of acute episodes of treatment-resistant bipolar disorder: a systematic review and exploratory meta-analysis of randomized controlled trials.
Topics: Bipolar Disorder; Depressive Disorder, Treatment-Resistant; Electroconvulsive Therapy; Humans; Ketam | 2020 |
The acute antisuicidal effects of single-dose intravenous ketamine and intranasal esketamine in individuals with major depression and bipolar disorders: A systematic review and meta-analysis.
Topics: Bipolar Disorder; Depression; Depressive Disorder, Major; Humans; Ketamine; Suicidal Ideation | 2021 |
Ketamine for Bipolar Depression: A Systematic Review.
Topics: Bipolar Disorder; Excitatory Amino Acid Antagonists; Humans; Ketamine | 2021 |
Pharmacodynamic Interactions Between Ketamine and Psychiatric Medications Used in the Treatment of Depression: A Systematic Review.
Topics: Antidepressive Agents; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Clozapine; Depressio | 2021 |
Ketamine's effect on inflammation and kynurenine pathway in depression: A systematic review.
Topics: Animals; Anti-Inflammatory Agents; Antidepressive Agents; Bipolar Disorder; Cytokines; Depressive Di | 2021 |
Ketamine for Depression, 2: Diagnostic and Contextual Indications.
Topics: Antidepressive Agents; Bipolar Disorder; Clinical Trials as Topic; Depressive Disorder, Major; Drug | 2017 |
Ketamine and Other Glutamate Receptor Modulators for Depression in Bipolar Disorder in Adults.
Topics: Adult; Bipolar Disorder; Depressive Disorder; Excitatory Amino Acid Antagonists; Humans; Ketamine | 2017 |
Comparison of the effect of intravenous anesthetics used for anesthesia during electroconvulsive therapy on the hemodynamic safety and the course of ECT.
Topics: Anesthetics; Anesthetics, Intravenous; Autonomic Nervous System; Bipolar Disorder; Depressive Disord | 2017 |
Is Ketamine the Future Clozapine for Depression? A Case Series and Literature Review on Maintenance Ketamine in Treatment-resistant Depression With Suicidal Behavior.
Topics: Adult; Antidepressive Agents; Bipolar Disorder; Depressive Disorder, Major; Depressive Disorder, Tre | 2018 |
Oral Ketamine for Depression: A Systematic Review.
Topics: Administration, Oral; Adolescent; Adult; Bipolar Disorder; Depressive Disorder, Major; Dose-Response | 2019 |
Rapid-acting antidepressant ketamine, its metabolites and other candidates: A historical overview and future perspective.
Topics: Animals; Antidepressive Agents; Bipolar Disorder; Depressive Disorder, Major; Excitatory Amino Acid | 2019 |
Efficacy and safety of ketamine in the management of anxiety and anxiety spectrum disorders: a review of the literature.
Topics: Anti-Anxiety Agents; Anxiety Disorders; Bipolar Disorder; Humans; Ketamine; Stress Disorders, Post-T | 2020 |
Beyond evidence-based treatment of bipolar disorder: Rational pragmatic approaches to management.
Topics: Ankyrins; Anticonvulsants; Antimanic Agents; Antipsychotic Agents; Anxiety Disorders; Bipolar Disord | 2019 |
Current status of ketamine and related compounds for depression.
Topics: Bipolar Disorder; Chemistry, Pharmaceutical; Depressive Disorder, Major; Humans; Ketamine | 2013 |
[Ketamine for treatment of acute depression].
Topics: Acute Disease; Analgesics, Short-Acting; Anesthetics, Dissociative; Antidepressive Agents; Bipolar D | 2013 |
A review of FDA-approved treatment options in bipolar depression.
Topics: Antidepressive Agents; Antidepressive Agents, Second-Generation; Antipsychotic Agents; Benzhydryl Co | 2013 |
A review of ketamine in affective disorders: current evidence of clinical efficacy, limitations of use and pre-clinical evidence on proposed mechanisms of action.
Topics: Animals; Antidepressive Agents; Bipolar Disorder; Combined Modality Therapy; Depression; Depressive | 2014 |
A review of ketamine in affective disorders: current evidence of clinical efficacy, limitations of use and pre-clinical evidence on proposed mechanisms of action.
Topics: Animals; Antidepressive Agents; Bipolar Disorder; Combined Modality Therapy; Depression; Depressive | 2014 |
A review of ketamine in affective disorders: current evidence of clinical efficacy, limitations of use and pre-clinical evidence on proposed mechanisms of action.
Topics: Animals; Antidepressive Agents; Bipolar Disorder; Combined Modality Therapy; Depression; Depressive | 2014 |
A review of ketamine in affective disorders: current evidence of clinical efficacy, limitations of use and pre-clinical evidence on proposed mechanisms of action.
Topics: Animals; Antidepressive Agents; Bipolar Disorder; Combined Modality Therapy; Depression; Depressive | 2014 |
A review of ketamine in affective disorders: current evidence of clinical efficacy, limitations of use and pre-clinical evidence on proposed mechanisms of action.
Topics: Animals; Antidepressive Agents; Bipolar Disorder; Combined Modality Therapy; Depression; Depressive | 2014 |
A review of ketamine in affective disorders: current evidence of clinical efficacy, limitations of use and pre-clinical evidence on proposed mechanisms of action.
Topics: Animals; Antidepressive Agents; Bipolar Disorder; Combined Modality Therapy; Depression; Depressive | 2014 |
A review of ketamine in affective disorders: current evidence of clinical efficacy, limitations of use and pre-clinical evidence on proposed mechanisms of action.
Topics: Animals; Antidepressive Agents; Bipolar Disorder; Combined Modality Therapy; Depression; Depressive | 2014 |
A review of ketamine in affective disorders: current evidence of clinical efficacy, limitations of use and pre-clinical evidence on proposed mechanisms of action.
Topics: Animals; Antidepressive Agents; Bipolar Disorder; Combined Modality Therapy; Depression; Depressive | 2014 |
A review of ketamine in affective disorders: current evidence of clinical efficacy, limitations of use and pre-clinical evidence on proposed mechanisms of action.
Topics: Animals; Antidepressive Agents; Bipolar Disorder; Combined Modality Therapy; Depression; Depressive | 2014 |
Ketamine administration in depressive disorders: a systematic review and meta-analysis.
Topics: Anesthetics, Dissociative; Antidepressive Agents; Bipolar Disorder; Depressive Disorder, Major; Depr | 2014 |
Ketamine administration in depressive disorders: a systematic review and meta-analysis.
Topics: Anesthetics, Dissociative; Antidepressive Agents; Bipolar Disorder; Depressive Disorder, Major; Depr | 2014 |
Ketamine administration in depressive disorders: a systematic review and meta-analysis.
Topics: Anesthetics, Dissociative; Antidepressive Agents; Bipolar Disorder; Depressive Disorder, Major; Depr | 2014 |
Ketamine administration in depressive disorders: a systematic review and meta-analysis.
Topics: Anesthetics, Dissociative; Antidepressive Agents; Bipolar Disorder; Depressive Disorder, Major; Depr | 2014 |
Ketamine administration in depressive disorders: a systematic review and meta-analysis.
Topics: Anesthetics, Dissociative; Antidepressive Agents; Bipolar Disorder; Depressive Disorder, Major; Depr | 2014 |
Ketamine administration in depressive disorders: a systematic review and meta-analysis.
Topics: Anesthetics, Dissociative; Antidepressive Agents; Bipolar Disorder; Depressive Disorder, Major; Depr | 2014 |
Ketamine administration in depressive disorders: a systematic review and meta-analysis.
Topics: Anesthetics, Dissociative; Antidepressive Agents; Bipolar Disorder; Depressive Disorder, Major; Depr | 2014 |
Ketamine administration in depressive disorders: a systematic review and meta-analysis.
Topics: Anesthetics, Dissociative; Antidepressive Agents; Bipolar Disorder; Depressive Disorder, Major; Depr | 2014 |
Ketamine administration in depressive disorders: a systematic review and meta-analysis.
Topics: Anesthetics, Dissociative; Antidepressive Agents; Bipolar Disorder; Depressive Disorder, Major; Depr | 2014 |
Ketamine administration in depressive disorders: a systematic review and meta-analysis.
Topics: Anesthetics, Dissociative; Antidepressive Agents; Bipolar Disorder; Depressive Disorder, Major; Depr | 2014 |
Ketamine administration in depressive disorders: a systematic review and meta-analysis.
Topics: Anesthetics, Dissociative; Antidepressive Agents; Bipolar Disorder; Depressive Disorder, Major; Depr | 2014 |
Ketamine administration in depressive disorders: a systematic review and meta-analysis.
Topics: Anesthetics, Dissociative; Antidepressive Agents; Bipolar Disorder; Depressive Disorder, Major; Depr | 2014 |
Ketamine administration in depressive disorders: a systematic review and meta-analysis.
Topics: Anesthetics, Dissociative; Antidepressive Agents; Bipolar Disorder; Depressive Disorder, Major; Depr | 2014 |
Ketamine administration in depressive disorders: a systematic review and meta-analysis.
Topics: Anesthetics, Dissociative; Antidepressive Agents; Bipolar Disorder; Depressive Disorder, Major; Depr | 2014 |
Ketamine administration in depressive disorders: a systematic review and meta-analysis.
Topics: Anesthetics, Dissociative; Antidepressive Agents; Bipolar Disorder; Depressive Disorder, Major; Depr | 2014 |
Ketamine administration in depressive disorders: a systematic review and meta-analysis.
Topics: Anesthetics, Dissociative; Antidepressive Agents; Bipolar Disorder; Depressive Disorder, Major; Depr | 2014 |
Ketamine administration in depressive disorders: a systematic review and meta-analysis.
Topics: Anesthetics, Dissociative; Antidepressive Agents; Bipolar Disorder; Depressive Disorder, Major; Depr | 2014 |
Ketamine administration in depressive disorders: a systematic review and meta-analysis.
Topics: Anesthetics, Dissociative; Antidepressive Agents; Bipolar Disorder; Depressive Disorder, Major; Depr | 2014 |
Ketamine administration in depressive disorders: a systematic review and meta-analysis.
Topics: Anesthetics, Dissociative; Antidepressive Agents; Bipolar Disorder; Depressive Disorder, Major; Depr | 2014 |
Ketamine administration in depressive disorders: a systematic review and meta-analysis.
Topics: Anesthetics, Dissociative; Antidepressive Agents; Bipolar Disorder; Depressive Disorder, Major; Depr | 2014 |
Ketamine administration in depressive disorders: a systematic review and meta-analysis.
Topics: Anesthetics, Dissociative; Antidepressive Agents; Bipolar Disorder; Depressive Disorder, Major; Depr | 2014 |
Ketamine administration in depressive disorders: a systematic review and meta-analysis.
Topics: Anesthetics, Dissociative; Antidepressive Agents; Bipolar Disorder; Depressive Disorder, Major; Depr | 2014 |
Ketamine administration in depressive disorders: a systematic review and meta-analysis.
Topics: Anesthetics, Dissociative; Antidepressive Agents; Bipolar Disorder; Depressive Disorder, Major; Depr | 2014 |
Ketamine administration in depressive disorders: a systematic review and meta-analysis.
Topics: Anesthetics, Dissociative; Antidepressive Agents; Bipolar Disorder; Depressive Disorder, Major; Depr | 2014 |
Ketamine administration in depressive disorders: a systematic review and meta-analysis.
Topics: Anesthetics, Dissociative; Antidepressive Agents; Bipolar Disorder; Depressive Disorder, Major; Depr | 2014 |
The use of ketamine as an antidepressant: a systematic review and meta-analysis.
Topics: Antidepressive Agents; Bipolar Disorder; Depressive Disorder, Major; Excitatory Amino Acid Antagonis | 2015 |
Ketamine and other glutamate receptor modulators for depression in bipolar disorder in adults.
Topics: Adult; Antidepressive Agents; Bipolar Disorder; Cytidine; Depression; Excitatory Amino Acid Antagoni | 2015 |
Meta-analysis of short- and mid-term efficacy of ketamine in unipolar and bipolar depression.
Topics: Antidepressive Agents; Bipolar Disorder; Clinical Trials as Topic; Depressive Disorder; Double-Blind | 2015 |
Efficacy of Ketamine in Bipolar Depression: Systematic Review and Meta-analysis.
Topics: Adult; Anhedonia; Bipolar Disorder; Excitatory Amino Acid Antagonists; Female; Humans; Ketamine; Mal | 2015 |
Single-dose infusion ketamine and non-ketamine N-methyl-d-aspartate receptor antagonists for unipolar and bipolar depression: a meta-analysis of efficacy, safety and time trajectories.
Topics: Antidepressive Agents; Bipolar Disorder; Depressive Disorder, Major; Excitatory Amino Acid Antagonis | 2016 |
Single-dose infusion ketamine and non-ketamine N-methyl-d-aspartate receptor antagonists for unipolar and bipolar depression: a meta-analysis of efficacy, safety and time trajectories.
Topics: Antidepressive Agents; Bipolar Disorder; Depressive Disorder, Major; Excitatory Amino Acid Antagonis | 2016 |
Single-dose infusion ketamine and non-ketamine N-methyl-d-aspartate receptor antagonists for unipolar and bipolar depression: a meta-analysis of efficacy, safety and time trajectories.
Topics: Antidepressive Agents; Bipolar Disorder; Depressive Disorder, Major; Excitatory Amino Acid Antagonis | 2016 |
Single-dose infusion ketamine and non-ketamine N-methyl-d-aspartate receptor antagonists for unipolar and bipolar depression: a meta-analysis of efficacy, safety and time trajectories.
Topics: Antidepressive Agents; Bipolar Disorder; Depressive Disorder, Major; Excitatory Amino Acid Antagonis | 2016 |
Single-dose infusion ketamine and non-ketamine N-methyl-d-aspartate receptor antagonists for unipolar and bipolar depression: a meta-analysis of efficacy, safety and time trajectories.
Topics: Antidepressive Agents; Bipolar Disorder; Depressive Disorder, Major; Excitatory Amino Acid Antagonis | 2016 |
Single-dose infusion ketamine and non-ketamine N-methyl-d-aspartate receptor antagonists for unipolar and bipolar depression: a meta-analysis of efficacy, safety and time trajectories.
Topics: Antidepressive Agents; Bipolar Disorder; Depressive Disorder, Major; Excitatory Amino Acid Antagonis | 2016 |
Single-dose infusion ketamine and non-ketamine N-methyl-d-aspartate receptor antagonists for unipolar and bipolar depression: a meta-analysis of efficacy, safety and time trajectories.
Topics: Antidepressive Agents; Bipolar Disorder; Depressive Disorder, Major; Excitatory Amino Acid Antagonis | 2016 |
Single-dose infusion ketamine and non-ketamine N-methyl-d-aspartate receptor antagonists for unipolar and bipolar depression: a meta-analysis of efficacy, safety and time trajectories.
Topics: Antidepressive Agents; Bipolar Disorder; Depressive Disorder, Major; Excitatory Amino Acid Antagonis | 2016 |
Single-dose infusion ketamine and non-ketamine N-methyl-d-aspartate receptor antagonists for unipolar and bipolar depression: a meta-analysis of efficacy, safety and time trajectories.
Topics: Antidepressive Agents; Bipolar Disorder; Depressive Disorder, Major; Excitatory Amino Acid Antagonis | 2016 |
Single-dose infusion ketamine and non-ketamine N-methyl-d-aspartate receptor antagonists for unipolar and bipolar depression: a meta-analysis of efficacy, safety and time trajectories.
Topics: Antidepressive Agents; Bipolar Disorder; Depressive Disorder, Major; Excitatory Amino Acid Antagonis | 2016 |
Single-dose infusion ketamine and non-ketamine N-methyl-d-aspartate receptor antagonists for unipolar and bipolar depression: a meta-analysis of efficacy, safety and time trajectories.
Topics: Antidepressive Agents; Bipolar Disorder; Depressive Disorder, Major; Excitatory Amino Acid Antagonis | 2016 |
Single-dose infusion ketamine and non-ketamine N-methyl-d-aspartate receptor antagonists for unipolar and bipolar depression: a meta-analysis of efficacy, safety and time trajectories.
Topics: Antidepressive Agents; Bipolar Disorder; Depressive Disorder, Major; Excitatory Amino Acid Antagonis | 2016 |
Single-dose infusion ketamine and non-ketamine N-methyl-d-aspartate receptor antagonists for unipolar and bipolar depression: a meta-analysis of efficacy, safety and time trajectories.
Topics: Antidepressive Agents; Bipolar Disorder; Depressive Disorder, Major; Excitatory Amino Acid Antagonis | 2016 |
Single-dose infusion ketamine and non-ketamine N-methyl-d-aspartate receptor antagonists for unipolar and bipolar depression: a meta-analysis of efficacy, safety and time trajectories.
Topics: Antidepressive Agents; Bipolar Disorder; Depressive Disorder, Major; Excitatory Amino Acid Antagonis | 2016 |
Single-dose infusion ketamine and non-ketamine N-methyl-d-aspartate receptor antagonists for unipolar and bipolar depression: a meta-analysis of efficacy, safety and time trajectories.
Topics: Antidepressive Agents; Bipolar Disorder; Depressive Disorder, Major; Excitatory Amino Acid Antagonis | 2016 |
Single-dose infusion ketamine and non-ketamine N-methyl-d-aspartate receptor antagonists for unipolar and bipolar depression: a meta-analysis of efficacy, safety and time trajectories.
Topics: Antidepressive Agents; Bipolar Disorder; Depressive Disorder, Major; Excitatory Amino Acid Antagonis | 2016 |
Single-dose infusion ketamine and non-ketamine N-methyl-d-aspartate receptor antagonists for unipolar and bipolar depression: a meta-analysis of efficacy, safety and time trajectories.
Topics: Antidepressive Agents; Bipolar Disorder; Depressive Disorder, Major; Excitatory Amino Acid Antagonis | 2016 |
Single-dose infusion ketamine and non-ketamine N-methyl-d-aspartate receptor antagonists for unipolar and bipolar depression: a meta-analysis of efficacy, safety and time trajectories.
Topics: Antidepressive Agents; Bipolar Disorder; Depressive Disorder, Major; Excitatory Amino Acid Antagonis | 2016 |
Single-dose infusion ketamine and non-ketamine N-methyl-d-aspartate receptor antagonists for unipolar and bipolar depression: a meta-analysis of efficacy, safety and time trajectories.
Topics: Antidepressive Agents; Bipolar Disorder; Depressive Disorder, Major; Excitatory Amino Acid Antagonis | 2016 |
Single-dose infusion ketamine and non-ketamine N-methyl-d-aspartate receptor antagonists for unipolar and bipolar depression: a meta-analysis of efficacy, safety and time trajectories.
Topics: Antidepressive Agents; Bipolar Disorder; Depressive Disorder, Major; Excitatory Amino Acid Antagonis | 2016 |
Single-dose infusion ketamine and non-ketamine N-methyl-d-aspartate receptor antagonists for unipolar and bipolar depression: a meta-analysis of efficacy, safety and time trajectories.
Topics: Antidepressive Agents; Bipolar Disorder; Depressive Disorder, Major; Excitatory Amino Acid Antagonis | 2016 |
Single-dose infusion ketamine and non-ketamine N-methyl-d-aspartate receptor antagonists for unipolar and bipolar depression: a meta-analysis of efficacy, safety and time trajectories.
Topics: Antidepressive Agents; Bipolar Disorder; Depressive Disorder, Major; Excitatory Amino Acid Antagonis | 2016 |
Single-dose infusion ketamine and non-ketamine N-methyl-d-aspartate receptor antagonists for unipolar and bipolar depression: a meta-analysis of efficacy, safety and time trajectories.
Topics: Antidepressive Agents; Bipolar Disorder; Depressive Disorder, Major; Excitatory Amino Acid Antagonis | 2016 |
Single-dose infusion ketamine and non-ketamine N-methyl-d-aspartate receptor antagonists for unipolar and bipolar depression: a meta-analysis of efficacy, safety and time trajectories.
Topics: Antidepressive Agents; Bipolar Disorder; Depressive Disorder, Major; Excitatory Amino Acid Antagonis | 2016 |
Single-dose infusion ketamine and non-ketamine N-methyl-d-aspartate receptor antagonists for unipolar and bipolar depression: a meta-analysis of efficacy, safety and time trajectories.
Topics: Antidepressive Agents; Bipolar Disorder; Depressive Disorder, Major; Excitatory Amino Acid Antagonis | 2016 |
KETAMINE FOR TREATMENT-RESISTANT UNIPOLAR AND BIPOLAR MAJOR DEPRESSION: CRITICAL REVIEW AND IMPLICATIONS FOR CLINICAL PRACTICE.
Topics: Antidepressive Agents; Bipolar Disorder; Depressive Disorder, Major; Depressive Disorder, Treatment- | 2016 |
Symptomatology and predictors of antidepressant efficacy in extended responders to a single ketamine infusion.
Topics: Adult; Alcohol-Related Disorders; Antidepressive Agents; Bipolar Disorder; Depressive Disorder, Majo | 2017 |
Administration of ketamine for unipolar and bipolar depression.
Topics: Bipolar Disorder; Depressive Disorder; Excitatory Amino Acid Antagonists; Humans; Ketamine | 2017 |
Ketamine as an alternative treatment for treatment-resistant depression.
Topics: Antidepressive Agents; Bipolar Disorder; Brain; Depressive Disorder, Major; Depressive Disorder, Tre | 2013 |
33 trials available for ketamine and Affective Psychosis, Bipolar
| Article | Year |
|---|---|
Arketamine for bipolar depression: Open-label, dose-escalation, pilot study.
Topics: Antidepressive Agents; Bipolar Disorder; Depression; Depressive Disorder, Major; Double-Blind Method | 2023 |
Maintenance of antidepressant and antisuicidal effects by D-cycloserine among patients with treatment-resistant depression who responded to low-dose ketamine infusion: a double-blind randomized placebo-control study.
Topics: Adult; Antidepressive Agents; Bipolar Disorder; Cycloserine; Depressive Disorder, Major; Depressive | 2019 |
Transient effects of multi-infusion ketamine augmentation on treatment-resistant depressive symptoms in patients with treatment-resistant bipolar depression - An open-label three-week pilot study.
Topics: Adult; Bipolar Disorder; Depression; Depressive Disorder, Treatment-Resistant; Female; Humans; Ketam | 2020 |
Cardiovascular effects of repeated subanaesthetic ketamine infusion in depression.
Topics: Antidepressive Agents; Bipolar Disorder; Blood Pressure; Cardiovascular System; Depressive Disorder, | 2021 |
Sleep improvement is associated with the antidepressant efficacy of repeated-dose ketamine and serum BDNF levels: a post-hoc analysis.
Topics: Adult; Antidepressive Agents; Bipolar Disorder; Brain-Derived Neurotrophic Factor; Depressive Disord | 2021 |
Ketamine augmentation of electroconvulsive therapy to improve neuropsychological and clinical outcomes in depression (Ketamine-ECT): a multicentre, double-blind, randomised, parallel-group, superiority trial.
Topics: Adult; Aged; Bipolar Disorder; Cognition; Cognition Disorders; Combined Modality Therapy; Comorbidit | 2017 |
A Randomized Pilot Study Comparing Ketamine and Methohexital Anesthesia for Electroconvulsive Therapy in Patients With Depression.
Topics: Adult; Aged; Anesthesia; Anesthesia, Intravenous; Anesthetics, Dissociative; Anesthetics, Intravenou | 2017 |
Ketamine versus midazolam in bipolar depression with suicidal thoughts: A pilot midazolam-controlled randomized clinical trial.
Topics: Adult; Anesthetics, Dissociative; Biomarkers; Bipolar Disorder; Brain-Derived Neurotrophic Factor; D | 2017 |
Anhedonia as a clinical correlate of suicidal thoughts in clinical ketamine trials.
Topics: Adult; Anesthetics, Dissociative; Anhedonia; Bipolar Disorder; Depression; Depressive Disorder, Majo | 2017 |
A randomized clinical trial of adjunctive ketamine anesthesia in electro-convulsive therapy for depression.
Topics: Adult; Anesthetics, Dissociative; Anesthetics, Intravenous; Antidepressive Agents; Bipolar Disorder; | 2018 |
Features of dissociation differentially predict antidepressant response to ketamine in treatment-resistant depression.
Topics: Adolescent; Adult; Aged; Antidepressive Agents; Bipolar Disorder; Depersonalization; Depressive Diso | 2018 |
Neurocognitive effects of six ketamine infusions and the association with antidepressant response in patients with unipolar and bipolar depression.
Topics: Adult; Antidepressive Agents; Bipolar Disorder; Cognition; Depressive Disorder, Major; Depressive Di | 2018 |
Vitamin B12 level may be related to the efficacy of single ketamine infusion in bipolar depression.
Topics: Adult; Aged; Bipolar Disorder; Excitatory Amino Acid Antagonists; Female; Folic Acid; Homocysteine; | 2013 |
Neural correlates of rapid antidepressant response to ketamine in bipolar disorder.
Topics: Adolescent; Adult; Aged; Antidepressive Agents; Bipolar Disorder; Brain; Brain Mapping; Cross-Over S | 2014 |
A pilot study of plasma metabolomic patterns from patients treated with ketamine for bipolar depression: evidence for a response-related difference in mitochondrial networks.
Topics: Adult; Antidepressive Agents; Biomarkers, Pharmacological; Bipolar Disorder; Cross-Over Studies; Dep | 2014 |
Clinical predictors of ketamine response in treatment-resistant major depression.
Topics: Adult; Bipolar Disorder; Body Mass Index; Depressive Disorder, Major; Depressive Disorder, Treatment | 2014 |
Anti-anhedonic effect of ketamine and its neural correlates in treatment-resistant bipolar depression.
Topics: Adolescent; Adult; Aged; Anhedonia; Bipolar Disorder; Brain; Cross-Over Studies; Depressive Disorder | 2014 |
Anti-anhedonic effect of ketamine and its neural correlates in treatment-resistant bipolar depression.
Topics: Adolescent; Adult; Aged; Anhedonia; Bipolar Disorder; Brain; Cross-Over Studies; Depressive Disorder | 2014 |
Anti-anhedonic effect of ketamine and its neural correlates in treatment-resistant bipolar depression.
Topics: Adolescent; Adult; Aged; Anhedonia; Bipolar Disorder; Brain; Cross-Over Studies; Depressive Disorder | 2014 |
Anti-anhedonic effect of ketamine and its neural correlates in treatment-resistant bipolar depression.
Topics: Adolescent; Adult; Aged; Anhedonia; Bipolar Disorder; Brain; Cross-Over Studies; Depressive Disorder | 2014 |
Single ketamine infusion and neurocognitive performance in bipolar depression.
Topics: Adult; Aged; Bipolar Disorder; Depression; Female; Humans; Infusions, Intravenous; Ketamine; Male; M | 2015 |
A single infusion of ketamine improves depression scores in patients with anxious bipolar depression.
Topics: Adult; Affect; Anxiety; Anxiety Disorders; Bipolar Disorder; Cross-Over Studies; Depression; Double- | 2015 |
Shank3 as a potential biomarker of antidepressant response to ketamine and its neural correlates in bipolar depression.
Topics: Adult; Aged; Amygdala; Antidepressive Agents; Biomarkers; Bipolar Disorder; Double-Blind Method; Fem | 2015 |
Rating depression over brief time intervals with the Hamilton Depression Rating Scale: standard vs. abbreviated scales.
Topics: Adult; Bipolar Disorder; Cross-Over Studies; Depression; Depressive Disorder, Major; Double-Blind Me | 2015 |
Single-dose ketamine followed by daily D-Cycloserine in treatment-resistant bipolar depression.
Topics: Adult; Bipolar Disorder; Cycloserine; Depressive Disorder, Treatment-Resistant; Drug Therapy, Combin | 2015 |
Lithium and Valproate Levels Do Not Correlate with Ketamine's Antidepressant Efficacy in Treatment-Resistant Bipolar Depression.
Topics: Adult; Antidepressive Agents; Bipolar Disorder; Cross-Over Studies; Depressive Disorder, Treatment-R | 2015 |
Ketamine for rapid reduction of suicidal ideation: a randomized controlled trial.
Topics: Adult; Bipolar Disorder; Depression; Depressive Disorder, Major; Double-Blind Method; Excitatory Ami | 2015 |
Ketamine for rapid reduction of suicidal ideation: a randomized controlled trial.
Topics: Adult; Bipolar Disorder; Depression; Depressive Disorder, Major; Double-Blind Method; Excitatory Ami | 2015 |
Ketamine for rapid reduction of suicidal ideation: a randomized controlled trial.
Topics: Adult; Bipolar Disorder; Depression; Depressive Disorder, Major; Double-Blind Method; Excitatory Ami | 2015 |
Ketamine for rapid reduction of suicidal ideation: a randomized controlled trial.
Topics: Adult; Bipolar Disorder; Depression; Depressive Disorder, Major; Double-Blind Method; Excitatory Ami | 2015 |
Ketamine for rapid reduction of suicidal ideation: a randomized controlled trial.
Topics: Adult; Bipolar Disorder; Depression; Depressive Disorder, Major; Double-Blind Method; Excitatory Ami | 2015 |
Ketamine for rapid reduction of suicidal ideation: a randomized controlled trial.
Topics: Adult; Bipolar Disorder; Depression; Depressive Disorder, Major; Double-Blind Method; Excitatory Ami | 2015 |
Ketamine for rapid reduction of suicidal ideation: a randomized controlled trial.
Topics: Adult; Bipolar Disorder; Depression; Depressive Disorder, Major; Double-Blind Method; Excitatory Ami | 2015 |
Ketamine for rapid reduction of suicidal ideation: a randomized controlled trial.
Topics: Adult; Bipolar Disorder; Depression; Depressive Disorder, Major; Double-Blind Method; Excitatory Ami | 2015 |
Ketamine for rapid reduction of suicidal ideation: a randomized controlled trial.
Topics: Adult; Bipolar Disorder; Depression; Depressive Disorder, Major; Double-Blind Method; Excitatory Ami | 2015 |
An assessment of the anti-fatigue effects of ketamine from a double-blind, placebo-controlled, crossover study in bipolar disorder.
Topics: Adult; Bipolar Disorder; Cross-Over Studies; Depressive Disorder, Treatment-Resistant; Double-Blind | 2016 |
Continuation phase intravenous ketamine in adults with treatment-resistant depression.
Topics: Adult; Antidepressive Agents; Bipolar Disorder; Depressive Disorder, Major; Depressive Disorder, Tre | 2016 |
Continuation phase intravenous ketamine in adults with treatment-resistant depression.
Topics: Adult; Antidepressive Agents; Bipolar Disorder; Depressive Disorder, Major; Depressive Disorder, Tre | 2016 |
Continuation phase intravenous ketamine in adults with treatment-resistant depression.
Topics: Adult; Antidepressive Agents; Bipolar Disorder; Depressive Disorder, Major; Depressive Disorder, Tre | 2016 |
Continuation phase intravenous ketamine in adults with treatment-resistant depression.
Topics: Adult; Antidepressive Agents; Bipolar Disorder; Depressive Disorder, Major; Depressive Disorder, Tre | 2016 |
Change in cytokine levels is not associated with rapid antidepressant response to ketamine in treatment-resistant depression.
Topics: Adult; Antidepressive Agents; Biomarkers; Bipolar Disorder; Cytokines; Depressive Disorder, Major; D | 2017 |
Ketamine augmentation rapidly improves depression scores in inpatients with treatment-resistant bipolar depression.
Topics: Adult; Aged; Aged, 80 and over; Antidepressive Agents; Bipolar Disorder; Depressive Disorder, Treatm | 2017 |
A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression.
Topics: Adolescent; Adult; Aged; Bipolar Disorder; Diagnostic and Statistical Manual of Mental Disorders; Do | 2010 |
A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression.
Topics: Adolescent; Adult; Aged; Bipolar Disorder; Diagnostic and Statistical Manual of Mental Disorders; Do | 2010 |
A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression.
Topics: Adolescent; Adult; Aged; Bipolar Disorder; Diagnostic and Statistical Manual of Mental Disorders; Do | 2010 |
A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression.
Topics: Adolescent; Adult; Aged; Bipolar Disorder; Diagnostic and Statistical Manual of Mental Disorders; Do | 2010 |
A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression.
Topics: Adolescent; Adult; Aged; Bipolar Disorder; Diagnostic and Statistical Manual of Mental Disorders; Do | 2010 |
A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression.
Topics: Adolescent; Adult; Aged; Bipolar Disorder; Diagnostic and Statistical Manual of Mental Disorders; Do | 2010 |
A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression.
Topics: Adolescent; Adult; Aged; Bipolar Disorder; Diagnostic and Statistical Manual of Mental Disorders; Do | 2010 |
A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression.
Topics: Adolescent; Adult; Aged; Bipolar Disorder; Diagnostic and Statistical Manual of Mental Disorders; Do | 2010 |
A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression.
Topics: Adolescent; Adult; Aged; Bipolar Disorder; Diagnostic and Statistical Manual of Mental Disorders; Do | 2010 |
A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression.
Topics: Adolescent; Adult; Aged; Bipolar Disorder; Diagnostic and Statistical Manual of Mental Disorders; Do | 2010 |
A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression.
Topics: Adolescent; Adult; Aged; Bipolar Disorder; Diagnostic and Statistical Manual of Mental Disorders; Do | 2010 |
A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression.
Topics: Adolescent; Adult; Aged; Bipolar Disorder; Diagnostic and Statistical Manual of Mental Disorders; Do | 2010 |
A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression.
Topics: Adolescent; Adult; Aged; Bipolar Disorder; Diagnostic and Statistical Manual of Mental Disorders; Do | 2010 |
A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression.
Topics: Adolescent; Adult; Aged; Bipolar Disorder; Diagnostic and Statistical Manual of Mental Disorders; Do | 2010 |
A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression.
Topics: Adolescent; Adult; Aged; Bipolar Disorder; Diagnostic and Statistical Manual of Mental Disorders; Do | 2010 |
A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression.
Topics: Adolescent; Adult; Aged; Bipolar Disorder; Diagnostic and Statistical Manual of Mental Disorders; Do | 2010 |
A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression.
Topics: Adolescent; Adult; Aged; Bipolar Disorder; Diagnostic and Statistical Manual of Mental Disorders; Do | 2010 |
A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression.
Topics: Adolescent; Adult; Aged; Bipolar Disorder; Diagnostic and Statistical Manual of Mental Disorders; Do | 2010 |
A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression.
Topics: Adolescent; Adult; Aged; Bipolar Disorder; Diagnostic and Statistical Manual of Mental Disorders; Do | 2010 |
A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression.
Topics: Adolescent; Adult; Aged; Bipolar Disorder; Diagnostic and Statistical Manual of Mental Disorders; Do | 2010 |
A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression.
Topics: Adolescent; Adult; Aged; Bipolar Disorder; Diagnostic and Statistical Manual of Mental Disorders; Do | 2010 |
A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression.
Topics: Adolescent; Adult; Aged; Bipolar Disorder; Diagnostic and Statistical Manual of Mental Disorders; Do | 2010 |
A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression.
Topics: Adolescent; Adult; Aged; Bipolar Disorder; Diagnostic and Statistical Manual of Mental Disorders; Do | 2010 |
A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression.
Topics: Adolescent; Adult; Aged; Bipolar Disorder; Diagnostic and Statistical Manual of Mental Disorders; Do | 2010 |
A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression.
Topics: Adolescent; Adult; Aged; Bipolar Disorder; Diagnostic and Statistical Manual of Mental Disorders; Do | 2010 |
A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression.
Topics: Adolescent; Adult; Aged; Bipolar Disorder; Diagnostic and Statistical Manual of Mental Disorders; Do | 2010 |
A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression.
Topics: Adolescent; Adult; Aged; Bipolar Disorder; Diagnostic and Statistical Manual of Mental Disorders; Do | 2010 |
A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression.
Topics: Adolescent; Adult; Aged; Bipolar Disorder; Diagnostic and Statistical Manual of Mental Disorders; Do | 2010 |
A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression.
Topics: Adolescent; Adult; Aged; Bipolar Disorder; Diagnostic and Statistical Manual of Mental Disorders; Do | 2010 |
A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression.
Topics: Adolescent; Adult; Aged; Bipolar Disorder; Diagnostic and Statistical Manual of Mental Disorders; Do | 2010 |
A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression.
Topics: Adolescent; Adult; Aged; Bipolar Disorder; Diagnostic and Statistical Manual of Mental Disorders; Do | 2010 |
A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression.
Topics: Adolescent; Adult; Aged; Bipolar Disorder; Diagnostic and Statistical Manual of Mental Disorders; Do | 2010 |
A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression.
Topics: Adolescent; Adult; Aged; Bipolar Disorder; Diagnostic and Statistical Manual of Mental Disorders; Do | 2010 |
A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression.
Topics: Adolescent; Adult; Aged; Bipolar Disorder; Diagnostic and Statistical Manual of Mental Disorders; Do | 2010 |
A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression.
Topics: Adolescent; Adult; Aged; Bipolar Disorder; Diagnostic and Statistical Manual of Mental Disorders; Do | 2010 |
A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression.
Topics: Adolescent; Adult; Aged; Bipolar Disorder; Diagnostic and Statistical Manual of Mental Disorders; Do | 2010 |
Simultaneous population pharmacokinetic modelling of ketamine and three major metabolites in patients with treatment-resistant bipolar depression.
Topics: Adult; Algorithms; Antidepressive Agents; Biotransformation; Bipolar Disorder; Cross-Over Studies; D | 2012 |
Replication of ketamine's antidepressant efficacy in bipolar depression: a randomized controlled add-on trial.
Topics: Adult; Bipolar Disorder; Cross-Over Studies; Depression; Double-Blind Method; Excitatory Amino Acid | 2012 |
Replication of ketamine's antidepressant efficacy in bipolar depression: a randomized controlled add-on trial.
Topics: Adult; Bipolar Disorder; Cross-Over Studies; Depression; Double-Blind Method; Excitatory Amino Acid | 2012 |
Replication of ketamine's antidepressant efficacy in bipolar depression: a randomized controlled add-on trial.
Topics: Adult; Bipolar Disorder; Cross-Over Studies; Depression; Double-Blind Method; Excitatory Amino Acid | 2012 |
Replication of ketamine's antidepressant efficacy in bipolar depression: a randomized controlled add-on trial.
Topics: Adult; Bipolar Disorder; Cross-Over Studies; Depression; Double-Blind Method; Excitatory Amino Acid | 2012 |
Replication of ketamine's antidepressant efficacy in bipolar depression: a randomized controlled add-on trial.
Topics: Adult; Bipolar Disorder; Cross-Over Studies; Depression; Double-Blind Method; Excitatory Amino Acid | 2012 |
Replication of ketamine's antidepressant efficacy in bipolar depression: a randomized controlled add-on trial.
Topics: Adult; Bipolar Disorder; Cross-Over Studies; Depression; Double-Blind Method; Excitatory Amino Acid | 2012 |
Replication of ketamine's antidepressant efficacy in bipolar depression: a randomized controlled add-on trial.
Topics: Adult; Bipolar Disorder; Cross-Over Studies; Depression; Double-Blind Method; Excitatory Amino Acid | 2012 |
Replication of ketamine's antidepressant efficacy in bipolar depression: a randomized controlled add-on trial.
Topics: Adult; Bipolar Disorder; Cross-Over Studies; Depression; Double-Blind Method; Excitatory Amino Acid | 2012 |
Replication of ketamine's antidepressant efficacy in bipolar depression: a randomized controlled add-on trial.
Topics: Adult; Bipolar Disorder; Cross-Over Studies; Depression; Double-Blind Method; Excitatory Amino Acid | 2012 |
Replication of ketamine's antidepressant efficacy in bipolar depression: a randomized controlled add-on trial.
Topics: Adult; Bipolar Disorder; Cross-Over Studies; Depression; Double-Blind Method; Excitatory Amino Acid | 2012 |
Replication of ketamine's antidepressant efficacy in bipolar depression: a randomized controlled add-on trial.
Topics: Adult; Bipolar Disorder; Cross-Over Studies; Depression; Double-Blind Method; Excitatory Amino Acid | 2012 |
Replication of ketamine's antidepressant efficacy in bipolar depression: a randomized controlled add-on trial.
Topics: Adult; Bipolar Disorder; Cross-Over Studies; Depression; Double-Blind Method; Excitatory Amino Acid | 2012 |
Replication of ketamine's antidepressant efficacy in bipolar depression: a randomized controlled add-on trial.
Topics: Adult; Bipolar Disorder; Cross-Over Studies; Depression; Double-Blind Method; Excitatory Amino Acid | 2012 |
Replication of ketamine's antidepressant efficacy in bipolar depression: a randomized controlled add-on trial.
Topics: Adult; Bipolar Disorder; Cross-Over Studies; Depression; Double-Blind Method; Excitatory Amino Acid | 2012 |
Replication of ketamine's antidepressant efficacy in bipolar depression: a randomized controlled add-on trial.
Topics: Adult; Bipolar Disorder; Cross-Over Studies; Depression; Double-Blind Method; Excitatory Amino Acid | 2012 |
Replication of ketamine's antidepressant efficacy in bipolar depression: a randomized controlled add-on trial.
Topics: Adult; Bipolar Disorder; Cross-Over Studies; Depression; Double-Blind Method; Excitatory Amino Acid | 2012 |
Replication of ketamine's antidepressant efficacy in bipolar depression: a randomized controlled add-on trial.
Topics: Adult; Bipolar Disorder; Cross-Over Studies; Depression; Double-Blind Method; Excitatory Amino Acid | 2012 |
Replication of ketamine's antidepressant efficacy in bipolar depression: a randomized controlled add-on trial.
Topics: Adult; Bipolar Disorder; Cross-Over Studies; Depression; Double-Blind Method; Excitatory Amino Acid | 2012 |
Replication of ketamine's antidepressant efficacy in bipolar depression: a randomized controlled add-on trial.
Topics: Adult; Bipolar Disorder; Cross-Over Studies; Depression; Double-Blind Method; Excitatory Amino Acid | 2012 |
Replication of ketamine's antidepressant efficacy in bipolar depression: a randomized controlled add-on trial.
Topics: Adult; Bipolar Disorder; Cross-Over Studies; Depression; Double-Blind Method; Excitatory Amino Acid | 2012 |
Replication of ketamine's antidepressant efficacy in bipolar depression: a randomized controlled add-on trial.
Topics: Adult; Bipolar Disorder; Cross-Over Studies; Depression; Double-Blind Method; Excitatory Amino Acid | 2012 |
Replication of ketamine's antidepressant efficacy in bipolar depression: a randomized controlled add-on trial.
Topics: Adult; Bipolar Disorder; Cross-Over Studies; Depression; Double-Blind Method; Excitatory Amino Acid | 2012 |
Replication of ketamine's antidepressant efficacy in bipolar depression: a randomized controlled add-on trial.
Topics: Adult; Bipolar Disorder; Cross-Over Studies; Depression; Double-Blind Method; Excitatory Amino Acid | 2012 |
Replication of ketamine's antidepressant efficacy in bipolar depression: a randomized controlled add-on trial.
Topics: Adult; Bipolar Disorder; Cross-Over Studies; Depression; Double-Blind Method; Excitatory Amino Acid | 2012 |
Replication of ketamine's antidepressant efficacy in bipolar depression: a randomized controlled add-on trial.
Topics: Adult; Bipolar Disorder; Cross-Over Studies; Depression; Double-Blind Method; Excitatory Amino Acid | 2012 |
Rapid antidepressant effect of ketamine in the electroconvulsive therapy setting.
Topics: Adolescent; Adult; Aged; Anesthesia; Anesthetics, Dissociative; Antidepressive Agents; Bipolar Disor | 2012 |
Neuropsychological and mood effects of ketamine in electroconvulsive therapy: a randomised controlled trial.
Topics: Adult; Affect; Bipolar Disorder; Cognition; Cognition Disorders; Depressive Disorder, Major; Double- | 2012 |
Neuropsychological and mood effects of ketamine in electroconvulsive therapy: a randomised controlled trial.
Topics: Adult; Affect; Bipolar Disorder; Cognition; Cognition Disorders; Depressive Disorder, Major; Double- | 2012 |
Neuropsychological and mood effects of ketamine in electroconvulsive therapy: a randomised controlled trial.
Topics: Adult; Affect; Bipolar Disorder; Cognition; Cognition Disorders; Depressive Disorder, Major; Double- | 2012 |
Neuropsychological and mood effects of ketamine in electroconvulsive therapy: a randomised controlled trial.
Topics: Adult; Affect; Bipolar Disorder; Cognition; Cognition Disorders; Depressive Disorder, Major; Double- | 2012 |
103 other studies available for ketamine and Affective Psychosis, Bipolar
| Article | Year |
|---|---|
Ketamine for treatment-resistant bipolar depression-need for more data!
Topics: Antidepressive Agents; Bipolar Disorder; Depressive Disorder, Treatment-Resistant; Humans; Infusions | 2021 |
Parental Attitudes Toward Use of Ketamine in Adolescent Mood Disorders and Suicidality.
Topics: Adolescent; Attitude; Bipolar Disorder; Child; Decision Making; Depressive Disorder, Major; Female; | 2021 |
The potential pro-cognitive effects with intravenous subanesthetic ketamine in adults with treatment-resistant major depressive or bipolar disorders and suicidality.
Topics: Adult; Bipolar Disorder; Cognition; Depressive Disorder, Major; Depressive Disorder, Treatment-Resis | 2021 |
Treatment-resistant bipolar disorder managed with ketamine infusions as monotherapy.
Topics: Bipolar Disorder; Depressive Disorder, Major; Humans; Infusions, Intravenous; Ketamine; Suicidal Ide | 2021 |
Oral racemic ketamine for common clinical contexts in patients with major depressive disorder: An important intervention that treatment guidelines may never include.
Topics: Antidepressive Agents; Bipolar Disorder; Depressive Disorder, Major; Depressive Disorder, Treatment- | 2022 |
Long-term outcomes of repeated ketamine infusions in patients with unipolar and bipolar depression: A naturalistic follow-up study.
Topics: Bipolar Disorder; Depressive Disorder, Treatment-Resistant; Follow-Up Studies; Humans; Infusions, In | 2022 |
Comparative effectiveness of repeated ketamine infusions in treating anhedonia in bipolar and unipolar depression.
Topics: Anhedonia; Bipolar Disorder; Depressive Disorder, Major; Humans; Infusions, Intravenous; Ketamine | 2022 |
Can ketamine be a safe option for treatment-resistant bipolar depression?
Topics: Antidepressive Agents; Bipolar Disorder; Depression; Depressive Disorder, Treatment-Resistant; Human | 2022 |
Changes in adipokine concentrations in antidepressant-resistant bipolar depression after ketamine infusion and electroconvulsive therapy.
Topics: Adipokines; Adiponectin; Antidepressive Agents; Bipolar Disorder; Electroconvulsive Therapy; Humans; | 2023 |
Efficacy and Safety of Subcutaneous Esketamine in the Treatment of Suicidality in Major Depressive Disorder and Bipolar Depression.
Topics: Administration, Intranasal; Antidepressive Agents; Bipolar Disorder; Depressive Disorder, Major; Dep | 2022 |
Comment on "Efficacy and Safety of Subcutaneous Esketamine in the Treatment of Suicidality in Major Depressive Disorder and Bipolar Depression".
Topics: Bipolar Disorder; Depressive Disorder, Major; Humans; Ketamine; Suicide | 2023 |
Comment on "Efficacy and Safety of Subcutaneous Esketamine in the Treatment of Suicidality in Major Depressive Disorder and Bipolar Depression".
Topics: Bipolar Disorder; Depressive Disorder, Major; Humans; Ketamine; Suicide | 2023 |
Comment on "Efficacy and Safety of Subcutaneous Esketamine in the Treatment of Suicidality in Major Depressive Disorder and Bipolar Depression".
Topics: Bipolar Disorder; Depressive Disorder, Major; Humans; Ketamine; Suicide | 2023 |
Comment on "Efficacy and Safety of Subcutaneous Esketamine in the Treatment of Suicidality in Major Depressive Disorder and Bipolar Depression".
Topics: Bipolar Disorder; Depressive Disorder, Major; Humans; Ketamine; Suicide | 2023 |
Comment on "Efficacy and Safety of Subcutaneous Esketamine in the Treatment of Suicidality in Major Depressive Disorder and Bipolar Depression".
Topics: Bipolar Disorder; Depressive Disorder, Major; Humans; Ketamine; Suicide | 2023 |
Comment on "Efficacy and Safety of Subcutaneous Esketamine in the Treatment of Suicidality in Major Depressive Disorder and Bipolar Depression".
Topics: Bipolar Disorder; Depressive Disorder, Major; Humans; Ketamine; Suicide | 2023 |
Comment on "Efficacy and Safety of Subcutaneous Esketamine in the Treatment of Suicidality in Major Depressive Disorder and Bipolar Depression".
Topics: Bipolar Disorder; Depressive Disorder, Major; Humans; Ketamine; Suicide | 2023 |
Comment on "Efficacy and Safety of Subcutaneous Esketamine in the Treatment of Suicidality in Major Depressive Disorder and Bipolar Depression".
Topics: Bipolar Disorder; Depressive Disorder, Major; Humans; Ketamine; Suicide | 2023 |
Comment on "Efficacy and Safety of Subcutaneous Esketamine in the Treatment of Suicidality in Major Depressive Disorder and Bipolar Depression".
Topics: Bipolar Disorder; Depressive Disorder, Major; Humans; Ketamine; Suicide | 2023 |
Authors' Response to Comment on "Efficacy and Safety of Subcutaneous Esketamine in the Treatment of Suicidality in Major Depressive Disorder and Bipolar Depression".
Topics: Bipolar Disorder; Depressive Disorder, Major; Humans; Ketamine; Suicide | 2023 |
Authors' Response to Comment on "Efficacy and Safety of Subcutaneous Esketamine in the Treatment of Suicidality in Major Depressive Disorder and Bipolar Depression".
Topics: Bipolar Disorder; Depressive Disorder, Major; Humans; Ketamine; Suicide | 2023 |
Authors' Response to Comment on "Efficacy and Safety of Subcutaneous Esketamine in the Treatment of Suicidality in Major Depressive Disorder and Bipolar Depression".
Topics: Bipolar Disorder; Depressive Disorder, Major; Humans; Ketamine; Suicide | 2023 |
Authors' Response to Comment on "Efficacy and Safety of Subcutaneous Esketamine in the Treatment of Suicidality in Major Depressive Disorder and Bipolar Depression".
Topics: Bipolar Disorder; Depressive Disorder, Major; Humans; Ketamine; Suicide | 2023 |
Authors' Response to Comment on "Efficacy and Safety of Subcutaneous Esketamine in the Treatment of Suicidality in Major Depressive Disorder and Bipolar Depression".
Topics: Bipolar Disorder; Depressive Disorder, Major; Humans; Ketamine; Suicide | 2023 |
Authors' Response to Comment on "Efficacy and Safety of Subcutaneous Esketamine in the Treatment of Suicidality in Major Depressive Disorder and Bipolar Depression".
Topics: Bipolar Disorder; Depressive Disorder, Major; Humans; Ketamine; Suicide | 2023 |
Authors' Response to Comment on "Efficacy and Safety of Subcutaneous Esketamine in the Treatment of Suicidality in Major Depressive Disorder and Bipolar Depression".
Topics: Bipolar Disorder; Depressive Disorder, Major; Humans; Ketamine; Suicide | 2023 |
Authors' Response to Comment on "Efficacy and Safety of Subcutaneous Esketamine in the Treatment of Suicidality in Major Depressive Disorder and Bipolar Depression".
Topics: Bipolar Disorder; Depressive Disorder, Major; Humans; Ketamine; Suicide | 2023 |
Authors' Response to Comment on "Efficacy and Safety of Subcutaneous Esketamine in the Treatment of Suicidality in Major Depressive Disorder and Bipolar Depression".
Topics: Bipolar Disorder; Depressive Disorder, Major; Humans; Ketamine; Suicide | 2023 |
Treating bipolar depression with esketamine: Safety and effectiveness data from a naturalistic multicentric study on esketamine in bipolar versus unipolar treatment-resistant depression.
Topics: Antidepressive Agents; Bipolar Disorder; Depression; Depressive Disorder, Treatment-Resistant; Human | 2023 |
Ketamine-Associated Change in Anhedonia and mTOR Expression in Treatment-Resistant Depression.
Topics: Anhedonia; Bipolar Disorder; Depression; Depressive Disorder, Treatment-Resistant; Humans; Ketamine; | 2023 |
Ketamine and its metabolites: Potential as novel treatments for depression.
Topics: Antidepressive Agents; Bipolar Disorder; Depression; Humans; Ketamine | 2023 |
Ketamine for Treatment-Resistant bipolar depression-A reality check!
Topics: Bipolar Disorder; Depressive Disorder, Treatment-Resistant; Excitatory Amino Acid Antagonists; Human | 2023 |
Pre-treatment functional connectivity of the cingulate cortex predicts anti-suicidal effects of serial ketamine infusions.
Topics: Adolescent; Adult; Aged; Bipolar Disorder; Depressive Disorder; Female; Gyrus Cinguli; Humans; Infus | 2023 |
Pain mediates the improvement of social functions of repeated intravenous ketamine in patients with unipolar and bipolar depression.
Topics: Bipolar Disorder; Depression; Depressive Disorder; Depressive Disorder, Treatment-Resistant; Humans; | 2023 |
Giovanni Martinotti: Treating bipolar depression with esketamine: Safety and effectiveness data from a naturalistic multicentric study on esketamine and bipolar × unipolar treatment resistant depression.
Topics: Bipolar Disorder; Depressive Disorder, Treatment-Resistant; Humans; Ketamine | 2023 |
Progress in treatment-resistant bipolar depression using repeated ketamine infusions.
Topics: Bipolar Disorder; Depression; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; | 2023 |
Ketamine infusions for treatment-resistant bipolar depression: Commentary.
Topics: Bipolar Disorder; Humans; Ketamine | 2023 |
Short term ketamine treatment in patient with bipolar disorder with comorbidity with borderline personality disorder: Focus on impulsivity.
Topics: Antidepressive Agents; Bipolar Disorder; Borderline Personality Disorder; Comorbidity; Female; Human | 2023 |
Repeated infusions of ketamine for treatment-resistant bipolar depression in real-world practice.
Topics: Bipolar Disorder; Depression; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; | 2023 |
The Association Between Body Mass Index and Remission Rates in Patients With Treatment-Resistant Depression Who Received Intravenous Ketamine.
Topics: Adult; Bipolar Disorder; Body Mass Index; Clinical Trials as Topic; Depressive Disorder, Treatment-R | 2019 |
Brain-derived neurotrophic factor-TrkB signaling and the mechanism of antidepressant activity by ketamine in mood disorders.
Topics: Animals; Antidepressive Agents; Bipolar Disorder; Brain-Derived Neurotrophic Factor; Humans; Ketamin | 2020 |
Baseline insomnia as a predictor of antidepressant efficacy to repeated intravenous ketamine for unipolar and bipolar depression: A preliminary study.
Topics: Antidepressive Agents; Bipolar Disorder; Depressive Disorder, Major; Humans; Infusions, Intravenous; | 2020 |
The effectiveness of ketamine on anxiety, irritability, and agitation: Implications for treating mixed features in adults with major depressive or bipolar disorder.
Topics: Adult; Anxiety; Bipolar Disorder; Depressive Disorder, Major; Depressive Disorder, Treatment-Resista | 2020 |
Safety and tolerability of IV ketamine in adults with major depressive or bipolar disorder: results from the Canadian rapid treatment center of excellence.
Topics: Adult; Bipolar Disorder; Canada; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistan | 2020 |
A preliminary study of adjunctive ketamine for treatment-resistant bipolar depression.
Topics: Antidepressive Agents; Bipolar Disorder; Depressive Disorder, Treatment-Resistant; Humans; Infusions | 2020 |
The effectiveness of repeated intravenous ketamine on depressive symptoms, suicidal ideation and functional disability in adults with major depressive disorder and bipolar disorder: Results from the Canadian Rapid Treatment Center of Excellence.
Topics: Adult; Bipolar Disorder; Canada; Depression; Depressive Disorder, Major; Depressive Disorder, Treatm | 2020 |
Changes in symptoms of anhedonia in adults with major depressive or bipolar disorder receiving IV ketamine: Results from the Canadian Rapid Treatment Center of Excellence.
Topics: Adult; Anhedonia; Bipolar Disorder; Canada; Depressive Disorder, Major; Humans; Ketamine; Retrospect | 2020 |
No evidence for the effectiveness of IV ketamine for treatment resistant mood disorders in retrospective study.
Topics: Adult; Anxiety; Bipolar Disorder; Depressive Disorder, Major; Depressive Disorder, Treatment-Resista | 2020 |
Comparative effectiveness of esketamine in the treatment of anhedonia in bipolar and unipolar depression.
Topics: Anhedonia; Antidepressive Agents; Bipolar Disorder; Humans; Ketamine | 2021 |
The effectiveness of intravenous ketamine in adults with treatment-resistant major depressive disorder and bipolar disorder presenting with prominent anxiety: Results from the Canadian Rapid Treatment Center of Excellence.
Topics: Administration, Intravenous; Adult; Anxiety; Anxiety Disorders; Bipolar Disorder; Canada; Depressive | 2021 |
Does body mass index predict response to intravenous ketamine treatment in adults with major depressive and bipolar disorder? Results from the Canadian Rapid Treatment Center of Excellence.
Topics: Adult; Antidepressive Agents; Bipolar Disorder; Body Mass Index; Canada; Depressive Disorder, Major; | 2022 |
Subanesthetic ketamine infusions for suicide ideation in patients with bipolar and unipolar treatment refractory depression.
Topics: Adult; Analgesics; Bipolar Disorder; Depressive Disorder, Major; Depressive Disorder, Treatment-Resi | 2021 |
Chronic lithium exposure attenuates ketamine-induced mania-like behavior and c-Fos expression in the forebrain of mice.
Topics: Amygdala; Animals; Antidepressive Agents; Antimanic Agents; Behavior, Animal; Bipolar Disorder; Depr | 2021 |
Comparative efficacy and side-effect profile of ketamine and esketamine in the treatment of unipolar and bipolar depression: protocol for a systematic review and network meta-analysis.
Topics: Bipolar Disorder; Drug-Related Side Effects and Adverse Reactions; Humans; Ketamine; Meta-Analysis a | 2021 |
Hypomania associated with high dose ketamine treatment.
Topics: Bipolar Disorder; Depressive Disorder, Major; Humans; Ketamine; Mania | 2021 |
Letter to the editor about "comparative effectiveness of esketamine in the treatment of anhedonia in bipolar and unipolar depression".
Topics: Anhedonia; Bipolar Disorder; Depressive Disorder; Humans; Ketamine | 2021 |
The effect of repeated doses of intravenous ketamine on measures of workplace attendance and productivity in adults with major depressive and bipolar disorder: Results from the canadian rapid treatment center of excellence.
Topics: Adult; Bipolar Disorder; Canada; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistan | 2021 |
Adjunctive music improves the tolerability of intravenous ketamine for bipolar depression.
Topics: Administration, Intravenous; Bipolar Disorder; Humans; Ketamine; Music | 2021 |
Ketamine-Induced Manic Episode.
Topics: Bipolar Disorder; Humans; Ketamine; Mania | 2021 |
The effect of intravenous ketamine on cognitive functions in adults with treatment-resistant major depressive or bipolar disorders: Results from the Canadian rapid treatment center of excellence (CRTCE).
Topics: Adult; Bipolar Disorder; Canada; Cognition; Depressive Disorder, Major; Depressive Disorder, Treatme | 2021 |
Does pre-treatment functioning influence response to intravenous ketamine in adults with treatment-resistant depression?
Topics: Adult; Bipolar Disorder; Depression; Depressive Disorder, Major; Depressive Disorder, Treatment-Resi | 2021 |
The meaningful change threshold as measured by the 16-item quick inventory of depressive symptomatology in adults with treatment-resistant major depressive and bipolar disorder receiving intravenous ketamine.
Topics: Adult; Bipolar Disorder; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Human | 2021 |
Ketamine-Induced Mania During Treatment for Complex Regional Pain Syndrome.
Topics: Analgesics; Animals; Bipolar Disorder; Complex Regional Pain Syndromes; Humans; Ketamine; Treatment | 2017 |
Motor-Activity Markers of Circadian Timekeeping Are Related to Ketamine's Rapid Antidepressant Properties.
Topics: Actigraphy; Adult; Affect; Aged; Antidepressive Agents; Bipolar Disorder; Circadian Rhythm; Depressi | 2017 |
A Survey of the Clinical, Off-Label Use of Ketamine as a Treatment for Psychiatric Disorders.
Topics: Antidepressive Agents; Antimanic Agents; Bipolar Disorder; Depressive Disorder; Health Care Surveys; | 2017 |
Efficacy of Esketamine in the Treatment of Depression With Psychotic Features: A Case Series.
Topics: Adult; Bipolar Disorder; Depressive Disorder, Major; Female; Humans; Ketamine; Male; Middle Aged; Ps | 2018 |
Potential Novel Treatments for Bipolar Depression: Ketamine, Fatty Acids, Anti-inflammatory Agents, and Probiotics.
Topics: Animals; Anti-Inflammatory Agents; Bipolar Disorder; Fatty Acids; Humans; Ketamine; Probiotics | 2017 |
Clinical experience using intranasal ketamine in the longitudinal treatment of juvenile bipolar disorder with fear of harm phenotype.
Topics: Administration, Intranasal; Adolescent; Adult; Bipolar Disorder; Child; Excitatory Amino Acid Antago | 2018 |
Use of ketamine for acute suicidal ideation in a patient with chronic pain on prescribed cannabinoids.
Topics: Adult; Bipolar Disorder; Cannabinoids; Chronic Pain; Humans; Injections, Intramuscular; Ketamine; Ma | 2017 |
Parsing the heterogeneity of depression: An exploratory factor analysis across commonly used depression rating scales.
Topics: Adult; Antidepressive Agents; Bipolar Disorder; Depressive Disorder, Major; Factor Analysis, Statist | 2018 |
Characterizing the course of suicidal ideation response to ketamine.
Topics: Adult; Bipolar Disorder; Depressive Disorder, Major; Diagnostic and Statistical Manual of Mental Dis | 2018 |
Antidepressant effect of repeated ketamine administration on kynurenine pathway metabolites in patients with unipolar and bipolar depression.
Topics: Administration, Intravenous; Adult; Antidepressive Agents; Bipolar Disorder; China; Chromatography, | 2018 |
Rapid and longer-term antidepressant effects of repeated-dose intravenous ketamine for patients with unipolar and bipolar depression.
Topics: Adult; Antidepressive Agents; Bipolar Disorder; Depressive Disorder, Major; Female; Humans; Infusion | 2018 |
Exploratory genome-wide association analysis of response to ketamine and a polygenic analysis of response to scopolamine in depression.
Topics: Adolescent; Adult; Aged; Antidepressive Agents; Bipolar Disorder; Depressive Disorder, Major; Female | 2018 |
Impact of midazolam vs. saline on effect size estimates in controlled trials of ketamine as a rapid-acting antidepressant.
Topics: Adult; Antidepressive Agents; Bipolar Disorder; Clinical Trials as Topic; Depressive Disorder, Major | 2019 |
Effects of chronic lithium exposure in a modified rodent ketamine-induced hyperactivity model of mania.
Topics: Animals; Behavior, Animal; Bipolar Disorder; Disease Models, Animal; Excitatory Amino Acid Antagonis | 2019 |
A preliminary study of anti-suicidal efficacy of repeated ketamine infusions in depression with suicidal ideation.
Topics: Adult; Antidepressive Agents; Asian People; Bipolar Disorder; China; Depressive Disorder, Major; Fem | 2019 |
Ketamine for the treatment of depression.
Topics: Antidepressive Agents; Bipolar Disorder; Depressive Disorder, Major; Depressive Disorder, Treatment- | 2013 |
Antidepressant, mood stabilizing and procognitive effects of very low dose sublingual ketamine in refractory unipolar and bipolar depression.
Topics: Administration, Sublingual; Adult; Affect; Aged; Aged, 80 and over; Antidepressive Agents; Bipolar D | 2013 |
Reply to: Subanesthetic dose ketamine does not induce an affective switch in three independent samples of treatment-resistant major depression.
Topics: Analgesics; Bipolar Disorder; Female; Humans; Ketamine; Reflex Sympathetic Dystrophy | 2013 |
Subanesthetic dose ketamine does not induce an affective switch in three independent samples of treatment-resistant major depression.
Topics: Analgesics; Bipolar Disorder; Female; Humans; Ketamine; Reflex Sympathetic Dystrophy | 2013 |
Sustained antidepressant response to ketamine.
Topics: Adult; Bipolar Disorder; Depressive Disorder, Major; Excitatory Amino Acid Antagonists; Female; Huma | 2013 |
Neuroprotective and antioxidant effects of curcumin in a ketamine-induced model of mania in rats.
Topics: Animals; Antimanic Agents; Antioxidants; Behavior, Animal; Bipolar Disorder; Catalase; Curcumin; Fem | 2014 |
Do the dissociative side effects of ketamine mediate its antidepressant effects?
Topics: Adult; Antidepressive Agents; Bipolar Disorder; Depressive Disorder, Major; Dissociative Disorders; | 2014 |
Do the dissociative side effects of ketamine mediate its antidepressant effects?
Topics: Adult; Antidepressive Agents; Bipolar Disorder; Depressive Disorder, Major; Dissociative Disorders; | 2014 |
Do the dissociative side effects of ketamine mediate its antidepressant effects?
Topics: Adult; Antidepressive Agents; Bipolar Disorder; Depressive Disorder, Major; Dissociative Disorders; | 2014 |
Do the dissociative side effects of ketamine mediate its antidepressant effects?
Topics: Adult; Antidepressive Agents; Bipolar Disorder; Depressive Disorder, Major; Dissociative Disorders; | 2014 |
Baseline vitamin B12 and folate levels do not predict improvement in depression after a single infusion of ketamine.
Topics: Administration, Intravenous; Adolescent; Adult; Aged; Bipolar Disorder; Depressive Disorder, Major; | 2014 |
The utility of the combination of dextromethorphan and quinidine in the treatment of bipolar II and bipolar NOS.
Topics: Adult; Bipolar Disorder; Dextromethorphan; Drug Administration Schedule; Drug Therapy, Combination; | 2014 |
Combined ketamine/transcranial magnetic stimulation treatment of severe depression in bipolar I disorder.
Topics: Adult; Bipolar Disorder; Combined Modality Therapy; Diagnostic and Statistical Manual of Mental Diso | 2014 |
A comment on Fond and colleagues' systematic review and meta-analysis of ketamine in the treatment of depressive disorders (Psychopharmacology 2014; Jul 20 [Epub ahead of print]).
Topics: Anesthetics, Dissociative; Antidepressive Agents; Bipolar Disorder; Depressive Disorder, Major; Depr | 2014 |
Ketamine's effectiveness in unipolar versus bipolar depression.
Topics: Anesthetics, Dissociative; Antidepressive Agents; Bipolar Disorder; Depressive Disorder, Major; Depr | 2014 |
Intensive ketamine use for multiple years: A case report.
Topics: Adult; Antidepressive Agents; Behavior, Addictive; Bipolar Disorder; Humans; Ketamine; Male; Self Me | 2015 |
Ketamine and transcranial magnetic stimulation treatment for bipolar II disorder: a case report.
Topics: Adult; Bipolar Disorder; Brain; Combined Modality Therapy; Humans; Ketamine; Male; Psychometrics; Re | 2015 |
Serine enantiomers as diagnostic biomarkers for schizophrenia and bipolar disorder.
Topics: Biomarkers; Bipolar Disorder; Excitatory Amino Acid Antagonists; Female; Humans; Ketamine; Male; Sch | 2016 |
Preventive Effect of Cecropia pachystachya Against Ketamine-Induced Manic Behavior and Oxidative Stress in Rats.
Topics: Animals; Behavior, Animal; Bipolar Disorder; Chromatography, High Pressure Liquid; Female; Hippocamp | 2015 |
Changes in cortical N-methyl-D-aspartate receptors and post-synaptic density protein 95 in schizophrenia, mood disorders and suicide.
Topics: Adult; Biomarkers; Bipolar Disorder; Depressive Disorder, Major; Disks Large Homolog 4 Protein; Fema | 2016 |
Benzodiazepines may reduce the effectiveness of ketamine in the treatment of depression.
Topics: Antidepressive Agents; Antimanic Agents; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; De | 2015 |
Assessing measures of suicidal ideation in clinical trials with a rapid-acting antidepressant.
Topics: Adolescent; Adult; Aged; Antidepressive Agents; Bipolar Disorder; Clozapine; Cross-Over Studies; Dep | 2015 |
Assessing measures of suicidal ideation in clinical trials with a rapid-acting antidepressant.
Topics: Adolescent; Adult; Aged; Antidepressive Agents; Bipolar Disorder; Clozapine; Cross-Over Studies; Dep | 2015 |
Assessing measures of suicidal ideation in clinical trials with a rapid-acting antidepressant.
Topics: Adolescent; Adult; Aged; Antidepressive Agents; Bipolar Disorder; Clozapine; Cross-Over Studies; Dep | 2015 |
Assessing measures of suicidal ideation in clinical trials with a rapid-acting antidepressant.
Topics: Adolescent; Adult; Aged; Antidepressive Agents; Bipolar Disorder; Clozapine; Cross-Over Studies; Dep | 2015 |
Possible Affective Switch Associated With Intravenous Ketamine Treatment in a Patient With Bipolar I Disorder.
Topics: Administration, Intravenous; Adult; Affect; Antidepressive Agents; Bipolar Disorder; Female; Humans; | 2016 |
Interaction of Ketamine and Cannabis in Bipolar Disorder.
Topics: Bipolar Disorder; Cannabis; Humans; Ketamine; Marijuana Abuse | 2016 |
Probable Ketamine-Induced Hypomanic-Like Episode in a Child With Cerebral Palsy.
Topics: Anesthetics, Dissociative; Bipolar Disorder; Cerebral Palsy; Child; Humans; Infusions, Intravenous; | 2016 |
Treatment of suicidal depression with ketamine in rapid cycling bipolar disorder.
Topics: Bipolar Disorder; Depression; Excitatory Amino Acid Antagonists; Female; Humans; Ketamine; Suicidal | 2016 |
The role of adipokines in the rapid antidepressant effects of ketamine.
Topics: Adipokines; Adiponectin; Adult; Antidepressive Agents; Bipolar Disorder; Depressive Disorder, Major; | 2017 |
The effects of edaravone in ketamine-induced model of mania in rats.
Topics: Analysis of Variance; Animals; Antimanic Agents; Antipyrine; Bipolar Disorder; Brain; Catalase; Dise | 2016 |
Ketamine-induced inhibition of glycogen synthase kinase-3 contributes to the augmentation of α-amino-3-hydroxy-5-methylisoxazole-4-propionic acid (AMPA) receptor signaling.
Topics: Animals; Antidepressive Agents; Bipolar Disorder; Disease Models, Animal; Disks Large Homolog 4 Prot | 2016 |
Preventive effects of blueberry extract on behavioral and biochemical dysfunctions in rats submitted to a model of manic behavior induced by ketamine.
Topics: Animals; Bipolar Disorder; Blueberry Plants; Brain; Catalase; Disease Models, Animal; Glutathione Pe | 2016 |
Evaluation of 50-kHz ultrasonic vocalizations in animal models of mania: Ketamine and lisdexamfetamine-induced hyperlocomotion in rats.
Topics: Animals; Antimanic Agents; Bipolar Disorder; Central Nervous System Stimulants; Disease Models, Anim | 2016 |
GSK-3: A key regulatory target for ketamine's rapid antidepressant effects mediated by enhanced AMPA to NMDA throughput.
Topics: alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Antidepressive Agents; Bipolar Disorder; G | 2016 |
N-methyl-D-aspartate glutamate receptor antagonists and the promise of rapid-acting antidepressants.
Topics: Antidepressive Agents; Bipolar Disorder; Drug Discovery; Excitatory Amino Acid Antagonists; Humans; | 2010 |
Research suggests new drug targets for depression. Pilot studies of ketamine intrigue scientists, but risks of this anesthetic limit its clinical use.
Topics: Anesthetics, Dissociative; Bipolar Disorder; Brain; Chronic Disease; Depressive Disorder, Major; Dou | 2010 |
Induction of prolonged mania during ketamine therapy for reflex sympathetic dystrophy.
Topics: Adult; Analgesics; Bipolar Disorder; Female; Humans; Ketamine; Reflex Sympathetic Dystrophy | 2011 |
Relationship of ketamine's plasma metabolites with response, diagnosis, and side effects in major depression.
Topics: Adult; Aged; Antidepressive Agents; Bipolar Disorder; Chromatography, Liquid; Cytochrome P-450 Enzym | 2012 |
Relationship of ketamine's plasma metabolites with response, diagnosis, and side effects in major depression.
Topics: Adult; Aged; Antidepressive Agents; Bipolar Disorder; Chromatography, Liquid; Cytochrome P-450 Enzym | 2012 |
Relationship of ketamine's plasma metabolites with response, diagnosis, and side effects in major depression.
Topics: Adult; Aged; Antidepressive Agents; Bipolar Disorder; Chromatography, Liquid; Cytochrome P-450 Enzym | 2012 |
Relationship of ketamine's plasma metabolites with response, diagnosis, and side effects in major depression.
Topics: Adult; Aged; Antidepressive Agents; Bipolar Disorder; Chromatography, Liquid; Cytochrome P-450 Enzym | 2012 |
Relationship of ketamine's plasma metabolites with response, diagnosis, and side effects in major depression.
Topics: Adult; Aged; Antidepressive Agents; Bipolar Disorder; Chromatography, Liquid; Cytochrome P-450 Enzym | 2012 |
Relationship of ketamine's plasma metabolites with response, diagnosis, and side effects in major depression.
Topics: Adult; Aged; Antidepressive Agents; Bipolar Disorder; Chromatography, Liquid; Cytochrome P-450 Enzym | 2012 |
Relationship of ketamine's plasma metabolites with response, diagnosis, and side effects in major depression.
Topics: Adult; Aged; Antidepressive Agents; Bipolar Disorder; Chromatography, Liquid; Cytochrome P-450 Enzym | 2012 |
Relationship of ketamine's plasma metabolites with response, diagnosis, and side effects in major depression.
Topics: Adult; Aged; Antidepressive Agents; Bipolar Disorder; Chromatography, Liquid; Cytochrome P-450 Enzym | 2012 |
Relationship of ketamine's plasma metabolites with response, diagnosis, and side effects in major depression.
Topics: Adult; Aged; Antidepressive Agents; Bipolar Disorder; Chromatography, Liquid; Cytochrome P-450 Enzym | 2012 |
Methoxetamine: from drug of abuse to rapid-acting antidepressant.
Topics: Anesthetics, Dissociative; Animals; Antidepressive Agents; Bipolar Disorder; Cyclohexanones; Cyclohe | 2012 |
Long-term maintenance with intramuscular ketamine for treatment-resistant bipolar II depression.
Topics: Bipolar Disorder; Excitatory Amino Acid Antagonists; Female; Humans; Injections, Intramuscular; Keta | 2012 |
Family history of alcohol dependence and antidepressant response to an N-methyl-D-aspartate antagonist in bipolar depression.
Topics: Adult; Alcoholism; Antidepressive Agents; Bipolar Disorder; Cross-Over Studies; Double-Blind Method; | 2012 |
Evaluation of behavioral and neurochemical changes induced by ketamine in rats: implications as an animal model of mania.
Topics: Animals; Antimanic Agents; Behavior, Animal; Bipolar Disorder; Disease Models, Animal; Drug Interact | 2012 |
Single ketamine infusion in bipolar depression resistant to antidepressants: are neurotrophins involved?
Topics: Adult; Aged; Antidepressive Agents; Biomarkers; Bipolar Disorder; Brain-Derived Neurotrophic Factor; | 2013 |
Clinical experience using intranasal ketamine in the treatment of pediatric bipolar disorder/fear of harm phenotype.
Topics: Administration, Intranasal; Adolescent; Bipolar Disorder; Child; Fear; Female; Humans; Ketamine; Mal | 2013 |
Clinical experience using intranasal ketamine in the treatment of pediatric bipolar disorder/fear of harm phenotype.
Topics: Administration, Intranasal; Adolescent; Bipolar Disorder; Child; Fear; Female; Humans; Ketamine; Mal | 2013 |
Clinical experience using intranasal ketamine in the treatment of pediatric bipolar disorder/fear of harm phenotype.
Topics: Administration, Intranasal; Adolescent; Bipolar Disorder; Child; Fear; Female; Humans; Ketamine; Mal | 2013 |
Clinical experience using intranasal ketamine in the treatment of pediatric bipolar disorder/fear of harm phenotype.
Topics: Administration, Intranasal; Adolescent; Bipolar Disorder; Child; Fear; Female; Humans; Ketamine; Mal | 2013 |
Comparison of seizure duration, ictal EEG, and cognitive effects of ketamine and methohexital anesthesia with ECT.
Topics: Aged; Aged, 80 and over; Anesthesia, Intravenous; Bipolar Disorder; Depressive Disorder, Major; Elec | 2003 |
Comparison of seizure duration, ictal EEG, and cognitive effects of ketamine and methohexital anesthesia with ECT.
Topics: Aged; Aged, 80 and over; Anesthesia, Intravenous; Bipolar Disorder; Depressive Disorder, Major; Elec | 2003 |
Comparison of seizure duration, ictal EEG, and cognitive effects of ketamine and methohexital anesthesia with ECT.
Topics: Aged; Aged, 80 and over; Anesthesia, Intravenous; Bipolar Disorder; Depressive Disorder, Major; Elec | 2003 |
Comparison of seizure duration, ictal EEG, and cognitive effects of ketamine and methohexital anesthesia with ECT.
Topics: Aged; Aged, 80 and over; Anesthesia, Intravenous; Bipolar Disorder; Depressive Disorder, Major; Elec | 2003 |
The psychotomimetic states inventory (PSI): measuring psychotic-type experiences from ketamine and cannabis.
Topics: Adolescent; Adult; Affective Symptoms; Anesthetics, Dissociative; Bipolar Disorder; Cognition Disord | 2008 |
Psychosis and ketamine.
Topics: Adult; Anesthetics; Bipolar Disorder; Burns; Chlorpromazine; Cyclohexanes; Female; Humans; Ketamine; | 1972 |